Foundation Healthcare (FDNH) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	FDNH
Entity Registrant Name	FOUNDATION HEALTHCARE, INC.
Entity Central Index Key	1272597
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,323,048
Entity Public Float			$3,034,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
ASSETS
Cash and cash equivalents	$2,860,025	$4,212,076
Accounts receivable, net of allowance for doubtful accounts of $1,741,571 and $4,778,915, respectively	18,971,435	12,755,642
Receivables from affiliates	1,157,184	848,002
Supplies inventories	1,863,175	1,931,142
Deferred tax asset	775,248	2,118,637
Prepaid and other current assets	3,712,625	2,184,248
Current assets from discontinued operations	342,441	518,629
Total current assets	29,682,133	24,568,376
Property and equipment, net	13,465,190	12,073,986
Equity method investments in affiliates	5,722,130	5,699,093
Intangible assets, net	9,080,395	11,138,621
Goodwill	973,927	973,927
Other assets	437,809	244,598
Other assets from discontinued operations	165,285	576,228
Total assets	59,526,869	55,274,829
Liabilities:
Accounts payable	10,364,160	11,648,987
Accrued liabilities	10,223,388	3,914,915
Preferred noncontrolling interests dividends payable	195,212	195,411
Short-term debt	456,784	5,664,827
Current portion of long-term debt	5,023,048	7,919,179
Other current liabilities	1,052,543	4,591,587
Current liabilities from discontinued operations	839,791	5,620,697
Total current liabilities	28,154,926	39,555,603
Long-term debt, net of current portion	24,737,719	10,031,732
Deferred lease incentive	8,608,716	5,563,984
Deferred tax liability	107,238	2,604,879
Other liabilities	5,317,075	4,086,946
Other liabilities from discontinued operations		9,969
Total liabilities	66,925,674	61,853,113
Preferred noncontrolling interests	8,700,000	8,700,000
Commitments and contingencies (Note 11)
Foundation HealthCare shareholders’ deficit:
Preferred stock $0.0001 par value, 10,000,000 authorized; no shares issued and outstanding
Common stock $0.0001 par value, 500,000,000 shares authorized; 17,263,842 and 16,383,489 issued and outstanding, respectively	1,726	1,638
Paid-in capital	19,321,267	18,256,501
Accumulated deficit	-37,265,044	-35,171,315
Total Foundation HealthCare shareholders’ deficit	-17,942,051	-16,913,176
Noncontrolling interests	1,843,246	1,634,892
Total deficit	-16,098,805	-15,278,284
Total liabilities, preferred noncontrolling interest and total deficit	$59,526,869	$55,274,829

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$1,741,571	$4,778,915
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	17,263,842	16,383,489
Common stock, shares outstanding	17,263,842	16,383,489

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net Revenues:
Patient services	$96,219,746	$81,121,802
Provision for doubtful accounts	-5,118,194	-3,755,035
Net patient services revenue	91,101,552	77,366,767
Management fees from affiliates	5,394,666	6,347,315
Other revenue	5,361,931	3,493,577
Revenues	101,858,149	87,207,659
Equity in earnings of affiliates	2,979,293	5,885,188
Operating Expenses:
Salaries and benefits	29,273,542	28,279,045
Supplies	24,000,276	22,871,118
Other operating expenses	42,767,477	32,830,312
Impairment of goodwill		21,864,781
Impairment of equity investment of affiliate	1,600,000	1,640,389
Depreciation and amortization	5,550,162	5,093,246
Total operating expenses	101,591,457	112,578,891
Other Income (Expense):
Interest expense, net	-1,610,791	-2,171,327
Gain on forgiveness of debt	7,108,562	7,108,562
Gain on sale-leaseback of real estate	3,961,277	3,961,277
Other income	385,033	144,776
Net other income (expense)	-1,225,758	9,043,288
Income (loss) from continuing operations, before taxes	2,020,227	-10,442,756
(Provision) benefit for income taxes	851,788	-3,777,113
Income (loss) from continuing operations, net of taxes	2,872,015	-14,219,869
Loss from discontinued operations, net of tax	-357,452	-839,238
Net Income (loss)	2,514,563	-15,059,107
Less: Net income attributable to noncontrolling interests	3,827,439	4,345,417
Net loss attributable to Foundation HealthCare	-1,312,876	-19,404,524
Preferred noncontrolling interests dividends	-780,853	-1,022,103
Net loss attributable to Foundation HealthCare common stock	-2,093,729	-20,426,627
Earnings per common share (basic and diluted):
Net loss from continuing operations attributable to Foundation HealthCare common stock.	($0.10)	($1.44)
Loss from discontinued operations, net of tax	($0.02)	($0.06)
Basic and diluted net income (loss) per share	($0.12)	($1.50)
Weighted average number of primary and diluted common shares outstanding	17,080,451	13,635,286
Pro Forma
Other Income (Expense):
(Provision) benefit for income taxes		-914,350
Net loss attributable to Foundation HealthCare common stock		($20,526,464)
Earnings per common share (basic and diluted):
Basic and diluted net income (loss) per share		($1.51)

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Deficit (USD $)	Total	Common Stock	Paid-in Capital	Accumulated Deficit	Noncontrolling Interest
Beginning Balances at Dec. 31, 2012	($13,341,187)	$1,145	$3,452,326	($14,744,688)	($2,049,970)
Beginning Balances, Shares at Dec. 31, 2012		11,450,000
Net loss attributable to Foundation HealthCare	-19,404,524			-19,404,524
Net income attributable to noncontrolling interests	4,345,417				4,345,417
Reverse acquisition	13,938,874	480	13,938,394
Reverse acquisition, Shares		4,802,328
Issuance of common stock and warrants	1,371,000	9	1,370,991
Issuance of common stock and warrants, Shares		87,000
Stock-based compensation	129,721	2	129,719
Stock-based compensation, Shares		22,594
Issuance of stock for payment of liabilities	108,537	2	108,535
Issuance of stock for payment of liabilities, Shares	24,700	24,700
Cancellation of outstanding shares, Shares		-3,133
Preferred noncontrolling interests dividends	-1,022,103			-1,022,103
Distributions to noncontrolling interests	-660,555				-660,555
Distributions to member	-743,464		-743,464
Ending Balances at Dec. 31, 2013	-15,278,284	1,638	18,256,501	-35,171,315	1,634,892
Ending Balances, Shares at Dec. 31, 2013		16,383,489
Net loss attributable to Foundation HealthCare	-1,312,876			-1,312,876
Net income attributable to noncontrolling interests	3,827,439				3,827,439
Stock-based compensation	1,064,854	88	1,064,766
Stock-based compensation, Shares		880,353
Preferred noncontrolling interests dividends	-780,853			-780,853
Distributions to noncontrolling interests	-3,731,252				-3,731,252
Proceeds from noncontrolling interests	112,167				112,167
Ending Balances at Dec. 31, 2014	($16,098,805)	$1,726	$19,321,267	($37,265,044)	$1,843,246
Ending Balances, Shares at Dec. 31, 2014		17,263,842

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating activities:
Net income (loss)	$2,514,563	($15,059,107)
Less: Loss from discontinued operations, net of tax	-357,452	-839,238
Income (loss) from continuing operations	2,872,015	-14,219,869
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization	5,550,162	5,093,246
Impairment of goodwill		21,864,781
Impairment of equity investment in affiliate	1,600,000	1,640,389
Deferred tax benefit	-1,154,252	-301,713
Stock-based compensation, net of cashless vesting	1,064,854	129,721
Gain on redemption of non-controlling interests		-66,915
Provision for doubtful accounts	5,118,194	3,755,035
Equity in earnings of affiliates	-2,979,293	-5,885,188
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net of provision for doubtful accounts	-11,333,987	-9,412,289
Receivables from affiliates	-309,182	197,483
Supplies Inventories	67,967	12,142
Prepaid and other current assets	-1,528,377	-81,786
Other assets	-193,211	134,489
Accounts payable	-1,284,827	-695,691
Accrued liabilities	6,383,015	-2,513,206
Income taxes payable		3,564,455
Other current liabilities	-3,613,586	827,132
Other liabilities	4,274,861	3,302,290
Net cash provided by operating activities from continuing operations	2,934,353	7,344,506
Net cash used in operating activities from discontinued operations	-488,300	-992,512
Net cash provided by operating activities	2,446,053	6,351,994
Investing activities:
Cash received in business acquisition		68,170
Purchase of property and equipment	-4,884,948	-6,368,276
Disposal of property and equipment	1,807	2,039,904
Sale of equity investment in affiliates	178,000
Distributions from affiliates	2,778,257	5,559,317
Net cash provided by (used in) investing activities from continuing operations	-1,926,884	1,299,115
Net cash provided by investing activities from discontinued operations		395,000
Net cash provided by (used in) investing activities	-1,926,884	1,694,115
Financing activities:
Debt proceeds	32,885,948	10,035,860
Debt payments	-26,284,135	-11,728,810
Common stock proceeds		435,000
Preferred noncontrolling interests proceeds		8,700,000
Preferred noncontrolling interests dividend	-781,052	-1,003,635
Redemption of preferred noncontrolling interests		-11,102,372
Distributions to noncontrolling interests	-3,731,252	-660,555
Proceeds from noncontrolling interests	112,167
Distributions to member		-743,464
Net cash provided by (used in) financing activities from continuing operations	2,201,676	-6,067,976
Net cash used in financing activities from discontinued operations	-4,072,896	-803,124
Net cash used in financing activities	-1,871,220	-6,871,100
Net change in cash and cash equivalents	-1,352,051	1,175,009
Cash and cash equivalents at beginning of year	4,212,076	3,037,067
Cash and cash equivalents at end of year	2,860,025	4,212,076
Cash Paid for Interest and Income Taxes:
Interest expense	2,052,213	2,366,345
Interest expense, discontinued operations	168,733	124,821
Income taxes, continuing operations	3,255,623
Noncash Investing and Financing Activities:
Common stock warrants issued	-936,000	-936,000
Common stock issued as payment for liabilities		-108,537
Seller financing - reverse acquisition		2,000,000
Debt and liabilities assumed - reverse acquisition		2,032,098
Debt issued in purchase of noncontrolling preferred interest		-2,339,905
Debt converted to common stock		($14,138,187)

Nature_of_Business

Nature of Business	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of Business	Note 1 – Nature of Business
	Foundation Healthcare, Inc. (the “Company”) is organized under the laws of the state of Oklahoma and owns controlling and noncontrolling interests in surgical hospitals located in Texas and Oklahoma.  The Company also owns noncontrolling interests in ambulatory surgery centers (“ASCs”) located in Texas, Pennsylvania, New Jersey, Maryland and Ohio.  The Company provides management services to a majority of the facilities that it has noncontrolling interests (referred to as “Affiliates”) under the terms of various management agreements.

Basis_of_Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation	Note 2 – Basis of Presentation
	Reverse Acquisition – On July 22, 2013, the Company acquired Foundation Surgery Affiliates, LLC (“FSA”) and FSA’s consolidated variable interest entity, Foundation Surgical Hospital Affiliates, LLC (“FSHA”) (collectively referred to as “Foundation”).  For accounting purposes, the acquisition of FSA was accounted for as a reverse acquisition and as a result, the Company’s historical operating results included in the accompanying consolidated financial statements for the periods prior to July 22, 2013 represent those of FSA.  The historical financial statements of FSA have been adjusted for the effect of the recapitalization that occurred as a result of the reverse acquisition.
	Going Concern and Management’s Plan – As of December 31, 2014, the Company had an accumulated deficit of $37.3 million and adjusted working capital deficit of $0.2 million (adjusted for redemption payments of $1.7 million payable to preferred noncontrolling interest holders in 2015).  During the year ended December 31, 2014, the Company generated a net loss attributable to Foundation Healthcare common stock of $2.1 million and generated cash flow from operating activities from continuing operations of $2.9 million.  As of December 31, 2014, the Company had cash and cash equivalents of $2.9 million and has access to a $2.5 million line of credit from its senior lender. Although the Company has access to a line of credit, management, based on existing operations and the due dates of certain liability and debt payments, projects the Company may not be able to meet all of its obligations as they become due in 2015.  Management plans to meet the projected cash flow shortage from management fees earned from new hospital partners the Company anticipates procuring in 2015.
	If management is unable to procure the management contracts as noted above, the Company may be forced to obtain extensions on existing debt and other obligations as they become due in 2015.  Although management has historically been successful in obtaining extensions, there is no assurance that the Company will be able to obtain them in the future.  In addition, management may choose to raise additional funds through the sale of equity or assets, but there is no assurance that the Company will be successful in completing such actions.
	If management is not able to obtain incremental management fees from new hospital partners, does not obtain extensions on some of its debt or other obligations during 2015 or if the Company is not able to raise additional funds through the sale of equity or assets, the Company may not have sufficient cash on hand or generate sufficient cash flow from operations to meet its cash requirements over the next 12 months.  These uncertainties raise substantial doubt about the Company’s ability to continue as a going concern.  The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Reverse Stock Split – At the Company’s annual meeting of stockholders held on May 12, 2014, the Company’s stockholders approved an amendment to our amended and restated certificate of incorporation to effect a reverse split of our common stock at a ratio between 1-for-3 to 1-for-10 shares.  The Company’s stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected by filing an appropriate amendment to our amended and restated certificate of incorporation.  The Company’s board of directors authorized the ratio of the reverse split and corresponding reduction in authorized shares on December 29, 2014 and effective at the close of business on January 8, 2015, the Company amended its amended and restated certificate of incorporation to effect a 1-for-10 reverse split of our common stock, or the Reverse Split.  The board of directors considered a ratio that would allow us to have a number of outstanding shares to have a sufficient trading volume while considering a stock price that would be consistent with our intention to eventually uplist of our common stock from the OTC Markets QB Tier to a listing on the NYSE MKT exchange, though there can be no assurance that we will ultimately pursue or be successful in seeking to uplist the Company’s common stock on such exchange.  The Board of Directors determined that a ratio of 1-for-10 was the best balance of these and other factors.  The effect of the reverse split reduced the Company’s outstanding common stock shares from 172,638,414 to 17,263,842 shares as of the date of the reverse split.  The accompanying consolidated financial statements give effect to the reverse split as of the first date reported.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies
	Consolidation – The accompanying consolidated financial statements include the accounts of Foundation Healthcare, Inc. and its wholly owned, majority owned and controlled subsidiaries.  All significant intercompany accounts and transactions have been eliminated in consolidation.
	The Company accounts for its investments in Affiliates in which the Company exhibits significant influence, but not control, in accordance with the equity method of accounting.  The Company does not consolidate its equity method investments, but rather measures them at their initial costs and then subsequently adjusts their carrying values through income for their respective shares of the earnings or losses during the period.  The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.
	Use of estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  Actual results could differ from those estimates.
	Reclassifications – Certain amounts presented in prior years have been reclassified to conform to the current year’s presentation.  Such reclassifications had no effect on net loss.
	Pro forma income information – Prior to July 22, 2013, FSA’s and FSHA’s member had elected to have FSA’s and FSHA’s income taxed as an S Corporation under provisions of the Internal Revenue Code and a similar section of the state income tax law.  Therefore, taxable income or loss is reported to the individual member for inclusion in its tax returns and no provision for income taxes is included in the Company’s consolidated financial statements for periods prior to July 22, 2013.  The pro forma income information provides an adjustment for income tax expense as if FSA and FSHA had been a C Corporation prior to July 22, 2013 at an assumed combined federal and state effective tax rate of 38%, which approximates the calculated statutory tax rates for the periods.
	Revenue recognition and accounts receivable – The Company recognizes revenues in the period in which services are performed and charged.  Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows.  Amounts the Company receives for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations, preferred provider organizations and other private insurers are generally less than the Company’s established billing rates.  Additionally, to provide for accounts receivable that could become uncollectible in the future, the Company establishes an allowance for doubtful accounts to reduce the carrying value of such receivables to their estimated net realizable value.  Accordingly, the revenues and accounts receivable reported in the Company’s consolidated financial statements are recorded at the net amount expected to be received.
	During the years ended December 31, 2014 and 2013, the Company’s revenue payor mix was as follows:
		2014				2013
	Medicare and Medicaid		24	%			29	%
	Commercial health insurance payors		67	%			59	%
	Patient self-pay		4	%			5	%
	Management fees from affiliates		5	%			7	%
	Other		5	%			4	%
	Provision for doubtful accounts		(5	%)			(4	%)
	Contractual Discounts and Cost Report Settlements – The Company derives a significant portion of its revenues from Medicare, Medicaid and other payors that receive discounts from its established billing rates.  The Company must estimate the total amount of these discounts to prepare its consolidated financial statements.  The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex and are subject to interpretation and adjustment.  The Company estimates the allowance for contractual discounts on a payor-specific basis given its interpretation of the applicable regulations or contract terms.  These interpretations sometimes result in payments that differ from the Company’s estimates.  Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.  Changes in estimates related to the allowance for contractual discounts affect revenues reported in the Company’s accompanying consolidated statements of operations.
	Cost report settlements under reimbursement agreements with Medicare and Medicaid are estimated and recorded in the period the related services are rendered and are adjusted in future periods as final settlements are determined.  There is a reasonable possibility that recorded estimates will change by a material amount in the near term.  The net cost report settlements due to the Company were approximately $617,955 and $235,000 at December 31, 2014 and 2013, respectively, and are in included in prepaid and other current assets in the accompanying consolidated balance sheets.  We adjusted our cost report estimate by $382,955 during 2014 based on our final filed cost report for 2013 and an estimate of the 2014 cost report. There was no adjustment for estimated cost report settlements in 2013.  The Company’s management believes that adequate provisions have been made for adjustments that may result from final determination of amounts earned under these programs.
	Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation.  The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements.  Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties and exclusion from the Medicare and Medicaid programs.
	Provision and Allowance for Doubtful Accounts – To provide for accounts receivable that could become uncollectible in the future, the Company establishes an allowance for doubtful accounts to reduce the carrying value of such receivables to their estimated net realizable value.  The primary uncertainty lies with uninsured patient receivables and deductibles, co-payments or other amounts due from individual patients.
	The Company has an established process to determine the adequacy of the allowance for doubtful accounts that relies on a number of analytical tools and benchmarks to arrive at a reasonable allowance.  No single statistic or measurement determines the adequacy of the allowance for doubtful accounts.  Some of the analytical tools that the Company utilizes include, but are not limited to, the aging of accounts receivable, historical cash collection experience, revenue trends by payor classification, the status of claims submitted to third party payors, reason codes for declined claims and an assessment of the Company’s ability to address the issue and resubmit the claim and whether a patient is on a payment plan and making payments consistent with that plan.  Accounts receivable are written off after collection efforts have been followed in accordance with the Company’s policies.
	Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values at the time products or services are provided.  Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available, which could have a material impact on the Company’s operating results and cash flows in subsequent periods.  Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.
	The patient and their third party insurance provider typically share in the payment for the Company’s products and services.  The amount patients are responsible for includes co-payments, deductibles, and amounts not covered due to the provider being out-of-network.  Due to uncertainties surrounding deductible levels and the number of out-of-network patients, the Company is not certain of the full amount of patient responsibility at the time of service.  The Company estimates amounts due from patients prior to service and generally collects those amounts prior to service.  Remaining amounts due from patients are then billed following completion of service.
	The activity in the allowances for doubtful accounts for the years ending December 31, 2014 and 2013 follows:
		2014				2013
	Balance at beginning of period	$	4,778,915			$	1,659,337
	Reclassification (to) from contractual allowance		(832,384	)			1,458,737
	Provisions recognized as reduction in revenues		5,118,194				3,755,035
	Write-offs, net of recoveries		(7,323,154	)			(2,094,194	)
	Balance at end of period	$	1,741,571			$	4,778,915
	Cash and cash equivalents – The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents.  Certificates of deposit with original maturities of more than three months are also considered cash equivalents if there are no restrictions on withdrawing funds from the account.
	Restricted cash – As of December 31, 2014 and 2013, the Company had restricted cash of approximately $700,000 and $701,000, respectively, included in prepaid and other current assets in the accompanying consolidated balance sheets.  The restricted cash is pledged as collateral against certain debt of the Company.
	Receivables from Affiliates – Receivables from Affiliates are stated at the amount billed to the Affiliates plus any accrued and unpaid interest.
	Supplies inventories – Supplies inventories are stated at the lower of cost or market and primarily include operating supplies used in the direct or indirect treatment of patients.  The Company accounts for inventories using the first in–first out method of accounting for substantially all of its inventories.
	Property and equipment – Property and equipment is stated at cost and depreciated using the straight line method to depreciate the cost of various classes of assets over their estimated useful lives.  At the time assets are sold or otherwise disposed of, the cost and accumulated depreciation are eliminated from the asset and depreciation accounts; profits and losses on such dispositions are reflected in current operations.  Fully depreciated assets are written off against accumulated depreciation.  Assets under capital leases are amortized using the straight-line method over the shorter of the estimated useful life of the assets or life of the lease term, excluding any lease renewals, unless the lease renewals are reasonably assured.  Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized.  Expenditures for maintenance and repairs are charged to expense as incurred.
	The estimated useful lives of the Company’s property and equipment are as follows:
	Asset Class		Useful Life
	Furniture and equipment		3 to 7 years
	Equipment under capital leases		3 to 7 years
	Leasehold improvements		5 to 10 years		or remaining lease period, whichever is shorter
	Long-lived assets – The Company evaluates its long-lived assets for possible impairment whenever circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future cash flows.  Fair value estimates are derived from established market values of comparable assets or internal calculations of estimated future net cash flows.  The Company’s estimates of future cash flows are based on assumptions and projections it believes to be reasonable and supportable.  The Company’s assumptions take into account revenue and expense growth rates, patient volumes, changes in payor mix and changes in legislation and other payor payment patterns.
	Goodwill and Intangible Assets – Goodwill is not amortized; instead, it is reviewed for impairment annually (in the fourth quarter) or more frequently if indicators of impairment exist or if a decision is made to sell a business.  A significant amount of judgment is involved in determining if an indicator of impairment has occurred.  Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others.  The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill.  Goodwill is allocated among and evaluated for impairment at the reporting unit level.
	The Financial Accounting Standards Board (FASB) guidance on testing goodwill for impairment provides an entity the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that the estimated fair value of a reporting unit is less than its carrying amount.  If an entity elects to perform a qualitative assessment and determines that an impairment is more likely than not, the entity is then required to perform the existing two-step quantitative impairment test (described below), otherwise no further analysis is required.  An entity also may elect not to perform the qualitative assessment and, instead, proceed directly to the two-step quantitative impairment test.  The ultimate outcome of the goodwill impairment review for a reporting unit should be the same whether an entity chooses to perform the qualitative assessment or proceeds directly to the two-step quantitative impairment test.
	The Company evaluates goodwill for impairment at least on an annual basis and more frequently if certain indicators are encountered.  Goodwill is to be tested at the reporting unit level, defined as an ASC or hospital (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount, including goodwill.  If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired.  The Company completed its annual impairment test as of December 31, 2014, and determined that goodwill was not impaired.
	Intangible assets other than goodwill which include customer relationships, customer files, covenants not to compete, trademarks and payor contracts are amortized over their estimated useful lives using the straight line method.  The remaining lives range from three to five years.  The Company evaluates the recoverability of identifiable intangible asset whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable.
	Noncontrolling Interests – Noncontrolling interests in the results of operations of consolidated subsidiaries represents the noncontrolling shareholders’ share of the income or loss of the various consolidated subsidiaries.  The noncontrolling interests in the consolidated balance sheet reflect the original investment by these noncontrolling shareholders in these consolidated subsidiaries, along with their proportional share of the earnings or losses of these subsidiaries less distributions made to these noncontrolling interest holders.
	Legal Issues – For asserted claims and assessments, liabilities are recorded when an unfavorable outcome of a matter is deemed to be probable and the loss is reasonably estimable.  Management determines the likelihood of an unfavorable outcome based on many factors such as the nature of the matter, available defenses and case strategy, progress of the matter, views and opinions of legal counsel and other advisors, applicability and success of appeals processes, and the outcome of similar historical matters, among others.  Once an unfavorable outcome is deemed probable, management weighs the probability of estimated losses, and the most reasonable loss estimate is recorded.  If an unfavorable outcome of a matter is deemed to be reasonably possible, then the matter is disclosed and no liability is recorded.  With respect to unasserted claims or assessments, management must first determine that the probability that an assertion will be made is likely, then, a determination as to the likelihood of an unfavorable outcome and the ability to reasonably estimate the potential loss is made.  Legal matters are reviewed on a continuous basis or sooner if significant changes in matters have occurred to determine if a change in the likelihood of an unfavorable outcome or the estimate of a loss is necessary.
	Concentration of credit risk – The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits.  The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk.  As of December 31, 2014 and 2013, the Company had cash deposits in excess of FDIC limits of $1.8 million and $3.4 million, respectively.
	Advertising Costs – Advertising costs are expensed as incurred.  Advertising expense for 2014 and 2013, included in continuing operations, was approximately $312,000 and $244,000, respectively.
	Acquisition Costs – Acquisition costs are charged directly to expense when incurred.
	Income Taxes – The Company recognizes deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect of deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  In the event the Company determines that the deferred tax assets will not be realized in the future, the valuation adjustment to the deferred tax assets is charged to earnings in the period in which the Company makes such a determination.
	The Company uses a two-step process to evaluate a tax position.  The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position.  The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements.  A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.
	Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.  Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met.  The Company reports tax-related interest and penalties as a component of income tax expense.
	Based on all known facts and circumstances and current tax law, the Company believes that the total amount of unrecognized tax benefits as of December 31, 2014, is not material to its results of operations, financial condition or cash flows.  The Company also believes that the total amount of unrecognized tax benefits as of December 31, 2014, if recognized, would not have a material effect on its effective tax rate.  The Company further believes that there are no tax positions for which it is reasonably possible, based on current tax law and policy that the unrecognized tax benefits will significantly increase or decrease over the next 12 months producing, individually or in the aggregate, a material effect on the Company’s results of operations, financial condition or cash flows.
	Loss per share – Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period.  Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted during the period.  Dilutive securities having an anti-dilutive effect on diluted earnings (loss) per share are excluded from the calculation.
	The dilutive potential common shares on options and warrants are calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all options and warrants are used to repurchase common stock at market value.  The amount of shares remaining after the proceeds are exhausted represents the potential dilutive effect of the securities.
	The following securities were not included in the computation of diluted earnings (loss) per share from continuing operations or discontinued operations as their effect would be anti-dilutive:
			2014		2013
	Stock options and warrants		1,622,796		1,836,106
	During 2014, management determined that the Company had incorrectly reflected the historical common stock shares attributable to Foundation and the common stock shares issued in the reverse acquisition.  As a result, the Company has restated its previously reported net income (loss) per share the year ended December 31, 2013 in order to correct certain previously reported amounts.  The restatement had no change on the ending number of common shares outstanding at December 31, 2013, but it did change the weighted average number of common and diluted outstanding shares used to calculate earnings per common share.  The restatement had no impact on assets, liabilities, total deficit or net income (loss) attributable to Foundation Healthcare common stock.
	The financial information included in the accompanying consolidated financial statements and notes thereto reflect the effects of the corrections described in the preceding paragraph.  The following tables set forth the correction of the individual affected line items in the accompanying consolidated financial statements:
			Year Ended December 31, 2013
			As Previously
			Reported				Correction			Restated
	Earnings per common share (basic and diluted):
Net loss from continuing operations attributable to Foundation Healthcare common stock							(0.24
		$	(1.20	)		$		)	$	(1.44	)
Loss from discontinued operations			(0.05	)			(0.01	)		(0.06	)
Net loss per share attributable to Foundation Healthcare common stock		$		)			(0.25
			(1.25			$		)	$	(1.50	)
Weighted average number of common and diluted shares outstanding							(2,657,727
			16,293,013					)		13,635,286
Pro forma basic and diluted net loss per share		$	(1.26	)		$	(0.25	)	$	(1.51	)
Stock options – The Company accounts for its stock option grants using the modified prospective method.  Under the modified prospective method, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period.
Recently Adopted and Recently Issued Accounting Guidance
Adopted Guidance
On January 2014, the Company adopted changes issued by the FASB to the accounting for obligations resulting from joint and several liability arrangements.  These changes require an entity to measure such obligations for which the total amount of the obligation is fixed at the reporting date as the sum of (i) the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors, and (ii) any additional amount the reporting entity expects to pay on behalf of its co-obligors.  An entity will also be required to disclose the nature and amount of the obligation as well as other information about those obligations.  Examples of obligations subject to these requirements are debt arrangements and settled litigation and judicial rulings.  The adoption of these changes had no impact on the Company’s consolidated financial statements, as the Company does not currently have any such arrangements.
On January 2014, the Company adopted changes issued by the FASB to the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.  These changes require an entity to present an unrecognized tax benefit as a liability in the financial statements if (i) a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position, or (ii) the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset to settle any additional income taxes that would result from the disallowance of a tax position.  Otherwise, an unrecognized tax benefit is required to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward.  Previously, there was diversity in practice as no explicit guidance existed.  These changes become effective for the Company on January 1, 2014. The adoption of these changes did not have a significant impact on the Company’s consolidated financial statements.
Issued Guidance
In April 2014, the FASB issued changes to the reporting of discontinued operations and disclosures of disposals of components of an entity. The amendments change the criteria for reporting discontinued operations while enhancing disclosures in this area. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Additionally, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income and expenses of discontinued operations. The amendments are effective prospectively for all disposals (or classifications as held for sale) of components of an entity, and for all businesses that, on acquisition, are classified as held for sale that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The Company is currently evaluating the new guidance to determine the impact it may have to its consolidated financial statements.
In May 2014, the FASB issued changes to the recognition of revenue from contracts with customers. These changes created a comprehensive framework for all entities in all industries to apply in the determination of when to recognize revenue, and, therefore, supersede virtually all existing revenue recognition requirements and guidance. This framework is expected to result in less complex guidance in application while providing a consistent and comparable methodology for revenue recognition. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this principle, an entity should apply the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract(s), (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract(s), and (v) recognize revenue when, or as, the entity satisfies a performance obligation. These changes become effective for the Company on January 1, 2017. Management is currently evaluating the potential impact of these changes on the Company’s consolidated financial statements.
In August 2014, the FASB issued changes to the disclosure of uncertainties about an entity’s ability to continue as a going concern. Under GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Even if an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. Because there is no guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related note disclosures, there is diversity in practice whether, when, and how an entity discloses the relevant conditions and events in its financial statements. As a result, these changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. These changes become effective for the Company for the 2016 annual period. Management has determined that the adoption of these changes will not have an impact on the Company’s consolidated financial statements. Subsequent to adoption, this guidance will need to be applied by management at the end of each annual period and interim period therein to determine what, if any, impact there will be on the consolidated financial statements in a given reporting period.

Reverse_Acquisition

Reverse Acquisition	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Reverse Acquisition	Note 4 – Reverse Acquisition
	On July 22, 2013, the Company acquired FSA and FSA’s consolidated variable interest entity, FSHA, from Foundation Healthcare Affiliates, LLC (“FHA”) pursuant to an Amended and Restated Membership Purchase Agreement (the “Purchase Agreement”).  Pursuant to the Purchase Agreement, the Company (i) issued to FHA 11,450,000 shares of its common stock, (ii) issued to FHA a demand promissory note in the principal amount of $2.0 million, and (iii) assumed certain liabilities and obligations of FHA totaling approximately $2.0 million.
	For accounting purposes, the acquisition of FSA was accounted for as a reverse acquisition and as a result, the Company’s historical operating results included in the accompanying consolidated financial statements for the periods prior to July 22, 2013 represent those of FSA.  The historical financial statements of FSA have been adjusted for the effect of the recapitalization that occurred as a result of the reverse acquisition.
	The acquisition of Foundation was based on management’s belief that Foundation’s acquisition and development strategy and operating model will enable the Company to grow by taking advantage of highly-fragmented markets, an increasing demand for short stay surgery and a need by physicians to forge strategic alliances to meet the needs of the evolving healthcare landscape while also shaping the clinical environments in which they practice.  The Company expects the acquisition of Foundation will generate positive earnings and cash flow that will be accretive to the earnings and cash flow of the Company.
	Simultaneous with and subject to the reverse acquisition, the Company issued 1,333,333 shares of common stock to purchase a $6.0 million participation in the credit facility owed by the Company to Arvest Bank (see Note 6 – Discontinued Operations for more information) and 1,797,030 shares of common stock to Mr. Roy T. Oliver, one of our greater than 5% shareholders and affiliates, for full satisfaction of debt owed to Mr. Oliver totaling $8,136,390.  Since the completion of the reverse acquisition was subject to these transactions, they have been recorded as part of the reverse acquisition.
	Since FSA is deemed to be the accounting acquirer, the reverse acquisition was recorded by allocating the purchase price of the acquisition to the assets acquired, including intangible assets and liabilities assumed, from the legacy business of Graymark Healthcare, Inc. (“Graymark”), based on their estimated fair values at the acquisition date.  The excess of the cost of the acquisitions over the net amounts assigned to the estimated fair value of the assets acquired, net of liabilities assumed, was recorded as goodwill, none of which is anticipated to be tax deductible.
	The fair value of the total consideration issued in the reverse acquisition amounted to $13.9 million and included the common stock attributable to existing Graymark shareholders and the issuance of the Company’s common stock to Arvest Bank and Mr. Oliver.
	The fair value amounts were initially recorded using preliminary estimates.  Subsequently, management engaged a third-party valuation company to complete a valuation of the fair value of the assets acquired and liabilities assumed in the reverse acquisition.  The preliminary and final purchase allocations for the reverse acquisition are as follows:
			Preliminary			Final
	Cash and cash equivalents		$	68,170		$	68,170
	Accounts receivable		249,333			249,333
	Current assets from discontinued operations		1,773,471			1,360,143
	Other current assets		198,977			198,976
	Total current assets		2,289,951			1,876,622
	Property and equipment		647,862			1,389,169
	Intangible assets		3,800,000			2,733,000
	Goodwill		20,847,608			21,864,781
	Other assets from discontinued operations		295,542			1,224,140
	Other assets		12,753			252,528
	Total assets acquired		27,893,716			29,340,240
	Liabilities assumed:
	Accounts payable and accrued liabilities		2,501,877			2,899,823
	Short term debt		2,000,000			2,000,000
	Current portion of long-term debt		714,711			714,711
	Current liabilities from discontinued operations		7,812,192			7,375,521
	Total current liabilities		13,028,780			12,990,055
	Long-term debt, net of current portion		742,385			742,385
	Other liabilities from discontinued operations		174,509			305,969
	Other liabilities		575,000			1,362,957
	Total liabilities assumed		14,520,674			15,401,366
	Net assets acquired		$	13,373,042		$	13,938,874
	During the year ended December 31, 2013, the Company incurred approximately $506,000 in expenses related to the reverse acquisition.  The expenses incurred related primarily to legal fees related to the Purchase Agreement and structure of the transaction and professional fees related to the audits of the 2012 and 2011 consolidated financial statements of FSA.
	The amounts of acquisition revenues and earnings included in the Company’s consolidated statements of operations for the year ended December 31, 2013, and the revenue and earnings of the combined entity had the reverse acquisition date for Graymark been January 1, 2013 are as follows:
					Loss From						Attributable to Foundation
		Revenue			Continuing Operations			Net Loss			Net Loss			Net Loss
														Per Share
	Actual:
	From 7/22/2013 to12/31/2013	$	968,729		$	(23,413,107	)	$	(24,995,058	)	$	(24,995,058	)
	Supplemental Pro Forma:
	From 1/1/2013 to 12/31/2013	$	94,514,058		$	(24,733,907	)	$	(19,402,769	)	$	(23,616,628	)	$	(1.73	)
	The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisition been consummated as of that time, nor is it intended to be a projection of future results.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2014
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	Note 5 – Discontinued Operations
	Prior to the reverse acquisition, Graymark committed to a plan to divest of or close certain sleep diagnostic and sleep therapy locations.  The decision was based on a combination of the financial performance of the facilities and the shift in focus to the business model of Foundation.  As a result of the pending closure or sale of these locations, the related assets, liabilities, results of operations and cash flows were classified as discontinued operations which were acquired by the Company in the reverse acquisition.
	Under the plan, from July 2013 to October 2013, Graymark closed or sold 24 sleep diagnostic locations including both IDTF and contracted locations in Georgia, Iowa, Kansas, Missouri, Nevada, Oklahoma and Texas and 5 sleep therapy locations in Iowa, Kansas, Nevada, Oklahoma and Texas.
	As part of the reverse acquisition, the Company acquired the special charge liability of $475,570 related to the estimated closing costs resulting from the plan to sell or close the sleep diagnostic and therapy locations.  For the years ended December 31, 2014 and 2013, the activity in the acquired accruals for restructuring charges established for lease termination and other exit costs were as follows:
			Lease Termination Cost				Other Exit Cost			Total
	Acquired balance at July 22, 2013		$	335,028			$	140,542		$	475,570
	Adjustments			(172,685	)			—			(172,685	)
	Cash Payments			(84,108	)			(140,542	)		(224,650	)
	Balance at December 31, 2013			78,235				—			78,235
	Adjustments			102,761				—			102,761
	Cash Payments			(70,575	)			—			(70,575	)
	Balance at December 31, 2014		$	110,421			$	—		$	110,421
	Additional charges may be recorded in future periods dependent upon the Company’s ability to sub-lease or otherwise mitigate future lease costs at closed facilities.
	The operating results of the discontinued sleep diagnostic and therapy locations and the Company’s other discontinued operations for the year ended December 31, 2014 and from July 22, 2013 to December 31, 2013 are summarized below:
			2014				July 22 to
							December 31,
							2013
	Revenue		$	123,728			$	877,362
	Loss before taxes		$	(576,535	)		$	(1,353,609	)
	Income tax benefit			219,083				514,371
	Loss from discontinued operations, net of tax		$	(357,452	)		$	(839,238	)
	The balance sheet items for discontinued operations as of December 31, 2014 and 2013 are summarized below:
		2014				2013
	Cash and cash equivalents	$	8,148			$	49,252
	Accounts receivable, net of allowances		—				222,943
	Inventories		—				1,893
	Other current assets		334,293				244,541
	Total current assets		342,441				518,629
	Fixed assets, net		165,285				426,228
	Other assets		—				150,000
	Total non-current assets		165,285				576,228
	Total assets	$	507,726			$	1,094,857
	Payables and accrued liabilities	$	839,791			$	1,557,771
	Short-term debt		—				3,994,932
	Current portion of long-term debt		—				67,994
	Total current liabilities		839,791				5,620,697
	Long-term debt, net of current portion		—				9,969
	Total liabilities	$	839,791			$	5,630,666
	The Company’s borrowings and capital lease obligations included in discontinued operations as of December 31, 2014 and 2013 are as follows:
			2014				2013
	Short-term debt
	Arvest Bank		$	—			$	3,994,932
	Long-term Debt
	Sleep center notes payable			—				28,723
	Equipment capital leases			—				49,389
	Total			—				78,112
	Less: Current portion of long term debt			—				(68,143	)
	Long term debt		$	—			$	9,969

Equity_Investments_in_Affiliat

Equity Investments in Affiliates	12 Months Ended
	Dec. 31, 2014
Investments In And Advances To Affiliates Schedule Of Investments [Abstract]
Equity Investments in Affiliates	Note 6 – Equity Investments in Affiliates
	The Company invests in non-majority interests in its Affiliates.  The Company’s equity investments and respective ownership interest as of December 31, 2014 and 2013 are as follows:
				Ownership %
	Affiliate	Location		2014				2013
	Surgical Hospitals:
	Grayson County Physicians Property, LLC	Sherman, TX			20	%			20	%
	Houston Orthopedic Hospital, LLC	Houston, TX			20	%			20	%
	ASCs:
	Foundation Surgery Affiliate of Nacogdoches, LLP	Nacogdoches, TX			13	%			13	%
	Kirby Glenn Surgery Center	Houston, TX			10	%			10	%
	Park Ten Surgery Center	Houston, TX			10	%			10	%
	Foundation Surgery Affiliate of Middleburg Heights, LLC	Middleburg Heights, OH			10	%			10	%
	Foundation Surgery Affiliate of Huntingdon Valley, LP	Huntingdon Valley, PA			20	%			20	%
	New Jersey Surgery Center, LLC	Mercerville, NJ			10	%			10	%
	Foundation Surgery Affiliate of Northwest Oklahoma City, LLC	Oklahoma City, OK			20	%			20	%
	Metropolitan Medial Partners, LLC ("Chevy Chase")	Chevy Chase, MD			0	%			18	%
	Cumberland Valley Surgery Center, LLC	Hagerstown, MD			32	%			32	%
	Frederick Surgical Center, LLC	Frederick, MD			20	%			20	%
	The results of operations and financial position for the years ended and as of December 31, 2014 and 2013, respectively, of the Company’s equity investments in Affiliates are as follows:
		2014				2013
	Net operating revenues	$	93,657,544			$	186,777,871
	Net income	$	22,016,318			$	40,559,684
	Current assets	$	20,145,429			$	44,091,846
	Noncurrent assets		40,297,744				44,668,968
	Total assets	$	60,443,173			$	88,760,814
	Current liabilities	$	13,343,319			$	31,891,679
	Noncurrent liabilities		21,489,753				29,015,316
	Total liabilities	$	34,833,073			$	60,906,995
	Members' equity	$	25,610,100			$	27,853,819
	The Master Agreement covering the Company’s ownership in Chevy Chase included a redemption feature that allowed the majority owner of Chevy Chase to purchase the Company’s 18% interest in Chevy Chase for $178,000.  In January 2014, the Company received notice from the majority owner that they intend to exercise their right to purchase the Company’s interest in October 2014 which is the term date of the Company’s management agreement.  Based on these facts, management concluded that the Company no longer has significant influence over Chevy Chase and, effective December 31, 2013, began accounting for Chevy Chase using the cost method of accounting versus the equity method previously used.  In addition, the Company performed an impairment analysis of the investment in Chevy Chase and determined that the projected cash distributions in 2014 from Chevy Chase would approximate the Company’s share in the earnings of Chevy Chase.  As a result, the Company recorded an impairment charge of $1.6 million to write-down the recorded investment down to $178,000.  The distributions that the Company received in 2014 were recorded as other revenue.  In October of 2014, the majority owner did exercise the right to purchase the Company’s interest for $178,000.  The amount received equaled our book value of the investment and did not result in a gain or loss on the transaction.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment
	Following are the components of property and equipment included in the accompanying consolidated balance sheets as of December 31, 2014 and 2013:
		2014			2013
	Equipment	$	22,813,790		$	21,799,376
	Equipment under capital lease		7,874,259			4,477,231
	Leasehold improvements		2,703,013			2,231,315
	Land		2,065,000			2,065,000
			35,456,062			30,572,922
	Accumulated depreciation		(21,990,872	)		(18,498,936	)
		$	13,465,190		$	12,073,986
	Depreciation expense for the years ended December 31, 2014 and 2013 was $5,550,161 and $3,228,009 respectively.

Goodwill_and_Other_Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	Note 8 – Goodwill and Other Intangibles
	Changes in the carrying amount of goodwill during the years ended December 31, 2014 and 2013 were as follows:
		2014				2013
	Balance, beginning of year	$	973,927			$	1,154,528
	Reverse acquisition		—				21,864,781
	Impairment charge		—				(21,864,781	)
	Finalization of valuation - Imaging Centers		—				(180,601	)
	Balance, end of year	$	973,927			$	973,927
	Goodwill and intangible assets with indefinite lives must be tested for impairment at least once a year.  Carrying values are compared with fair values, and when the carrying value exceeds the fair value, the carrying value of the impaired asset is reduced to its fair value.  The Company tests goodwill for impairment on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist.  The performance of the test involves a two-step process.  The first step of the impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill.  The Company generally determines the fair value of its reporting units using the income approach methodology of valuation that includes the discounted cash flow method as well as other generally accepted valuation methodologies.  If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the Company performs the second step of the goodwill impairment test to determine the amount of impairment loss.  The second step of the goodwill impairment test involves comparing the implied fair value of the affected reporting unit’s goodwill with the carrying value of that goodwill.
	The goodwill associated with the reverse acquisition was $21,864,781.  Based on the sleep study trends and forecasted cash flows for the Company’s sleep operations that will continue to be operated, management determined that an impairment indicator existed at the time of the reverse acquisition.  The Company then determined the projected cash flows from the continuing operations of the legacy Graymark business were not sufficient to support the recorded goodwill.  Based on assumptions similar to those that market participants would make in valuing the sleep diagnostic operations, the Company evaluated the fair value of the goodwill subsequent to the reverse acquisition and determined the acquired goodwill was fully-impaired.
	Changes in the carrying amount of intangible assets during the years ended December 31, 2014 and 2013 were as follows:
		Carrying				Accumulated
		Amount				Amortization				Net
	1-Jan-13	$	11,791,500			$	(1,520,642	)		$	10,270,858
	Business Acquisition		2,733,000				—				2,733,000
	Amortization		—				(1,865,237	)			(1,865,237	)
	31-Dec-13		14,524,500				(3,385,879	)			11,138,621
	Amortization		—				(2,058,226	)			(2,058,226	)
	31-Dec-14	$	14,524,500			$	(5,444,105	)		$	9,080,395
	Intangible assets as of December 31, 2014 and 2013 include the following:
				2014
		Useful		Carrying				Accumulated						2013
		Life (Years)		Value				Amortization				Net		Net
	Management fee contracts	8-Jun		$	3,498,500			$	(2,169,907	)		$	1,328,593	$	1,763,463
	Non-compete	5			2,027,000				(849,667	)			1,177,333		1,583,256
	Physician memberships	7			6,468,000				(2,002,000	)			4,466,000		5,390,000
	Trade Name	5			381,000				(110,962	)			270,038		347,218
	Service Contracts	10			2,150,000				(311,569	)			1,838,431		2,054,684
				$	14,524,500			$	(5,444,105	)		$	9,080,395	$	11,138,621
	Amortization expense for the next five years related to these intangible assets is expected to be as follows:
	Year ended December 31,
	2015	$	2,055,474
	2016		2,055,474
	2017		1,994,629
	2018		1,226,387
	2019		985,000
	Thereafter		763,431

Borrowings_and_Capital_Lease_O

Borrowings and Capital Lease Obligations	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Borrowings and Capital Lease Obligations	Note 9 – Borrowings and Capital Lease Obligations
	The Company’s short-term debt obligations as of December 31, 2014 and 2013 are as follows:
		Rate (1)		2014			2013
	Note payable - Legacy			$	—		$	2,814,027
	Note payable - S&H leasing				—			1,865,600
	Note payable - working capital				—			800,000
	Insurance premium financings	3.9 - 4.9%			456,784			101,135
	Note payable - Medicare cost report				—			84,065
	Short-term debt			$	456,784		$	5,664,827
	(1) Effective rate as of December 31, 2014
	The Company has various insurance premium financing notes payable that bear interest rates ranging from 3.9% to 4.9%.  The insurance notes mature from January 2015 to October 2015 and the Company is required to make monthly principal and interest payments totaling $154,064.
	The Company’s long-term debt and capital lease obligations as of December 31, 2014 and 2013 are as follows:
		Rate (1)				Maturity	2014			2013
						Date
	Senior Lender:
	Note payable		4.40%			Jul. 2021	$	25,750,000		$	—
	Other Lenders:
	Line of credit							—			896,000
	Notes payable - working capital							—			3,715,088
	Note payable - equity investments							—			3,270,427
	Note payable - management agreements							—			640,466
	Note payable - assumption							—			146,857
	Note payable - preferred interest redemption							—			5,100,000
	Note payable - settlements							—			1,189,725
	Note payable - THE							—			311,149
	Notes payable - physician partners							—			103,604
	Notes payable - acquisition							—			99,610
	Capital Lease Obligations	5.5 - 10.7%				Feb. 2015 -		4,010,767			2,477,985
						Dec. 2020
	Total							29,760,767			17,950,911
	Less: Current portion of long-term debt							(5,023,048	)		(7,919,179	)
	Long-term debt						$	24,737,719		$	10,031,732
	(1) Effective rate as of December 31, 2014
	SNB Credit Facility
	Effective June 30, 2014, we entered into a Loan Agreement with Bank SNB, National Association, and Texas Capital Bank, together referred to as Lenders and collectively the agreement is referred to as the SNB Credit Facility.  The SNB Credit Facility was used to consolidate substantially all of our and our subsidiaries’ debt in the principal amount of $27.5 million, which we refer to as the Term Loan, and provides for an additional revolving loan in the amount of $2.5 million, which we refer to as the Revolving Loan.  As of June 30, 2014 we have not drawn funds from the Revolving Loan.  We have also entered into a number of ancillary agreements in connection with the SNB Credit Facility, including deposit account control agreements, subsidiary guarantees, security agreements and promissory notes.
	Maturity Dates.  The Term Loan matures on June 30, 2021 and the Revolving Loan matures on June 30, 2016.
	Interest Rates.  The interest rate for the Term Loan and Revolving Loan is 30-day LIBOR plus the Applicable Margins based on our Senior Debt Ratio, as defined.
	The Applicable Margins are as follows:
		Applicable Margin
	Senior Debt Ratio	Revolving Loan	Term Loan
	≥ 2.5x	3.75%	4.25%
	< 2.5x, but ≥ 2.0x	3.25%	3.75%
	< 2.0 x	2.75%	3.25%
	The Applicable Margins are established at 3.75% for the Revolving Loan and 4.25% for the Term Loan through December 31, 2014.  Subsequent to December 31, 2014, the Applicable Margins will be adjusted on a quarterly basis based on our senior debt ratio. The Senior Debt Ratio is calculated by dividing all of our indebtedness, including capital leases, which is secured by a lien or security interest in any of our assets by our EBITDA for the preceding four fiscal quarters.  EBITDA is defined in the SNB Credit Facility as our net income calculated before interest expense, provision for income taxes, depreciation and amortization expenses, stock compensation, gains arising from the write-up of assets, extraordinary gains and any one-time expenses approved by Bank SNB.
	Interest and Principal Payments.  We are required to make quarterly payments of principal and interest on the Term Loan.  The first four quarterly payments on the Term Loan will be $875,000 plus all accrued and unpaid interest.  Each subsequent quarterly payment will be $1,000,000 plus all accrued and unpaid interest.  We are required to make quarterly payments on the Revolving Loan equal to the accrued and unpaid interest.  All unpaid principal and interest on the Term Loan and Revolving Loan must be paid on the respective maturity dates of June 30, 2021 and June 30, 2016.
	Permitted Acquisitions.  We must obtain the Lenders approval for any acquisition, merger or consolidation in which the consideration paid for the acquisition, merger or consolidation is in excess of $1 million or for any acquisition, merger or consolidation in which the target entity’s operating income for the preceding 12 month period is less than zero.
	Mandatory Prepayments.  If we sell any assets in excess of $100,000 or collectively sell any assets in a 12 month period in excess of $100,000, we must make a prepayment equal to the net proceeds of the asset sale(s).  If we receive proceeds from a debt or equity offering that is not used for a permitted acquisition over a 12 month period following the offering or for repayment of our preferred noncontrolling interests, we must make a prepayment equal to the net proceeds of the debt or equity offering.  Subsequent to the completion of our annual audited financial statements, we must make a prepayment equal to 30% of our Excess Cash Flow which is defined as the amount of EBITDA (as defined in the SNB Credit Facility) for the fiscal year that exceeds the sum of debt service payments plus capital expenditures plus cash payments for federal, state and local income taxes, plus distributions made by our Equity Owned Hospitals to persons other than us.  Our expected mandatory prepayment related to Excess Cash Flow in 2014 is $533,884
	Voluntary Prepayments.  We may prepay amounts under the Term Loan at any time provided that we are required to pay a prepayment penalty of 2% of the amount prepaid if payment is made prior to the first anniversary, 1.5% if the prepayment is made after the first anniversary but prior to the second anniversary and 1% if the prepayment is made after the second anniversary but prior to the maturity date.  We may prepay amounts under the Revolving Loan at any time without penalty.
	Guaranties.  Each of our direct or indirect wholly-owned subsidiaries jointly and severally and unconditionally guaranty payment of our obligations owed to Lenders.
	Financial Covenants:
	Senior Debt Ratio.  We must maintain a Senior Debt Ratio not in excess of 3.00 to 1.00 as of the end of each fiscal quarter beginning with the quarter ending September 30, 2014.  As of December 30, 2014, our Senior Debt Ratio was 1.76.
	Senior Debt Service Coverage Ratio.  We must maintain a Senior Debt Service Coverage Ratio of not less than 1.30 to 1.00 as of the end of each fiscal quarter beginning with the quarter ending September 30, 2014. The Senior Debt Service Coverage ratio is the ratio of EBITDA (as defined in the SNB Credit Facility) for the preceding four fiscal quarters minus cash payments for federal, state and local taxes, minus capital expenditures to our debt service payments for the same period.  As of December 31, 2014, our Senior Debt Service Coverage Ratio was 2.07.
	Adjusted Senior Debt Service Coverage Ratio.  We must maintain an Adjusted Senior Debt Service Coverage Ratio of not less than 1.05 to 1.00 as of the end of each fiscal quarter beginning with the quarter ending September 30, 2014. The Adjusted Senior Debt Service Coverage Ratio is the ratio of EBITDA (as defined in the SNB Credit Facility) for the preceding four fiscal quarters minus cash payments for federal, state and local taxes, minus capital expenditures, plus distributions made to our preferred noncontrolling interest holders, plus distributions made by our Equity Owned Hospitals to persons other than us to our debt service payments for the same period.  As of December 31, 2014, our Adjusted Senior Debt Service Ratio was 1.41.
	Annualized EBITDA.  Until June 30, 2015 and for purposes of calculating compliance with the financial covenants in SNB Credit Facility, EBITDA shall be determined by annualizing EBITDA for the fiscal quarter ending on December 31, 2014 and each quarter that has elapsed thereafter.
	As of December 31, 2014, the Company is in compliance with all of the SNB Credit Facility financial covenants.
	Restrictions on Indebtedness.  We and our Equity Owned Hospitals are not allowed to create any indebtedness other than indebtedness for the purchase of fixed assets not exceeding $500,000 in any fiscal year, trade payables incurred in the ordinary course of business and not past due, contingent obligations and unsecured indebtedness not exceeding $100,000 in the aggregate at any time outstanding.
	Use of Proceeds.  All proceeds of the Term Loan were used solely for the refinancing of existing indebtedness.  The proceeds of the Revolving Loan will be used for working capital.
	Collateral.  Payment and performance of our obligations under the SNB Credit Facility are secured in general by all of our assets.
	Defaults and Remedies.  In addition to the general defaults of failure to perform our obligations under the Loan Agreement, events of default also include the occurrence of a change in control, as defined, and the loss of our Medicare or Medicaid certification, collateral casualties, entry of a judgment of $150,000 or more, failure of first liens on collateral and the termination of any of our management agreements that represent more than 10% of our management fees for the preceding 18 month period.  In the event of a monetary default, all of our obligations due under the SNB Credit Facility shall become immediately due and payable.  In the event of a non-monetary default, we have 10 days or in some cases three days to cure before bankSNB has the right to declare our obligations due under the SNB Credit Facility immediately due and payable.
	At December 31, 2014, future maturities of long-term debt were as follows:
	Year ended December 31:
	2015	$	5,023,048
	2016		4,781,929
	2017		4,613,541
2018		4,604,681
2019		4,625,161
Thereafter		6,112,407

Preferred_Noncontrolling_Inter

Preferred Noncontrolling Interests	12 Months Ended
	Dec. 31, 2014
Noncontrolling Interest [Abstract]
Preferred Noncontrolling Interests	Note 10 –Preferred Noncontrolling Interests
	On March 13, 2013, the Company’s wholly-owned subsidiary, Foundation Health Enterprises, LLC (“FHE”) initiated a private placement offering for up to $15,960,000.  The offering was comprised of 152 units (“FHE Unit” or “preferred noncontrolling interest”).  Each FHE Unit was offered at $105,000 and entitled the purchaser to one (1) Class B membership interest in FHE, valued at $100,000, and 1,000 shares of the Company’s common stock, valued at $5,000.  During July 2013 to October 2013, FHE and the Company completed the sale of 87 FHE Units for total consideration of $9,135,000 which was comprised of $8,700,000 attributable to the preferred noncontrolling interest and $435,000 attributable to the 87,000 shares of the Company’s common stock.
	The FHE Units provide for a cumulative preferred annual return of 9% on the amount allocated to the Class B membership interests.  The FHE Units will be redeemed by FHE in four annual installments beginning in July 2014.  The FHE Unit holders agreed to defer the first installment until March 2015.  The first three installments shall be in the amount of $10,000 per FHE Unit and the fourth installment will be in the amount of the unreturned capital contribution and any undistributed preferred distributions.  The FHE Units are convertible at the election of the holder at any time prior to the complete redemption into restricted common shares of the Company at a conversion price of $20.00 per share.  Since the FHE Units have a redemption feature and a conversion feature which the Company determined to be substantive, the preferred noncontrolling interests has been recorded at the mezzanine level in the accompanying consolidated balance sheets and the corresponding dividends are recorded as a reduction of accumulated deficit.
	As of December 31, 2012, the Company had an outstanding preferred membership interest of $11,072,465.  The preferred member interest was owned by Tyche Health Enterprises, LLC (“Tyche”) and provided for annual cash dividends at a rate of 11.5%.  On March 31, 2013, the Company entered into an Asset Purchase Agreement (the “Tyche Agreement”) with Tyche which was subsequently amended on March 31, 2013 and amended and closed on July 22, 2013.  Under the Tyche Agreement, the Company purchased from Tyche (i) all of Tyche’s right, title and interest in the Membership Interest Purchase Agreement; (ii) all of Tyche’s right, title and interest in the preferred and common membership interest in FSH and the right to various equity interests in the affiliates of FSH; (iii) all of Tyche’s right, title and interest in the preferred and common membership interest in FSHA and the right to various equity interest in the affiliates of FSHA; and (iv) all of Tyche’s right, title and interest in any preferred or non-preferred ownership interest in any Foundation entities that have been acquired as a result of the Membership Interest Purchase Agreement.
	Under the Tyche Agreement, the Company paid $11,102,372 to Tyche and Tyche related entities and TSH issued promissory notes totaling $2,339,905 to Tyche and Tyche related entities for total consideration of $13,442,277.  As further consideration for the Tyche Agreement, the Company issued Tyche and certain Tyche related entities warrants for the purchase of Company’s common stock.  The warrants issued included:
	1	Five year warrants for the purchase of a total of 193,750 shares of the Company’s common stock at a strike price of $10.00 per share;
	2	Seven and one-half year warrants for the purchase of a total of 351,620 shares of the Company’s common stock at a strike price of $13.50 per share; and
	3	Ten year warrants for the purchase of a total of 229,630 shares of the Company’s common stock at a strike price of $16.00 per share.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 – Commitments and Contingencies
	Legal Issues – The Company is exposed to asserted and unasserted legal claims encountered in the normal course of business, including claims for damages for personal injuries, medical malpractice, breach of contracts, wrongful restriction of or interference with physicians’ staff privileges and employment related claims.  In certain of these actions, plaintiffs request payment for damages, including punitive damages that may not be covered by insurance.  Management believes that the ultimate resolution of these matters will not have a material adverse effect on the operating results or the financial position of the Company.  During the years ended December 31, 2014 and 2013, the Company did not incur any settlement expenses related to its ongoing asserted and unasserted legal claims.
	Operating Leases – The Company leases all of the real property used in its business for office space, surgical hospital facilities and certain medical equipment under operating lease agreements.  Rent expense for leases that contain scheduled rent increases is recognized on a straight-line basis over the lease term (“Deferred Rent”).  As of December 31, 2014 and 2013, the Company had Deferred Rent of $3,930,325 and $6,648,369, respectively, which is included in other liabilities in the accompanying consolidated balance sheets.  In addition to minimum lease payments, certain leases require reimbursement for common area maintenance and insurance, which are expensed when incurred.
	The Company’s rental expense, net of sublease income, for operating leases in 2014 and 2013 was $9,933,563 and $7,112,362, respectively.
	Following is a summary of the future minimum lease payments under operating leases as of December 31, 2014:
	2015	$	11,675,379
	2016		11,760,275
	2017		11,826,286
	2018		11,737,775
	2019		11,431,044
	Thereafter		84,661,254
	Less: Sublease income		(3,457,542	)
	Total	$	139,634,471
	At December 31, 2014 and 2013, the Company had current and long-term deferred lease incentives of $9,555,581 and $5,563,984, respectively.  The lease incentives are included in current other liabilities and other liabilities the accompanying consolidated balance sheets and are amortized on a straight line basis over the life of the lease as a reduction in rent expense.
	Self-insurance – Effective January 1, 2014, the Company began using a combination of insurance and self-insurance for employee-related healthcare benefits. The self-insurance liability is determined actuarially, based on the actual claims filed and an estimate of incurred but not reported claims. Self-insurance reserves as of December 31, 2014 were $560,851 and are included in accrued liabilities in the accompanying consolidated balance sheets.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Note 12 – Income Taxes
	Prior to July 22, 2013, FSA’s and FSHA’s member had elected to have FSA’s and FSHA’s income taxed as an S Corporation under provisions of the Internal Revenue Code and a similar section of the state income tax law.  Therefore, taxable income or loss is reported to the individual member for inclusion in its tax returns and no provision for income taxes is included in the Company’s consolidated financial statements for periods prior to July 22, 2013.  The pro forma income information provides an adjustment for income tax expense as if FSA and FSHA had been a C Corporation prior to July 22, 2013 at an assumed combined federal and state effective tax rate of 38%, which approximates the calculated statutory tax rates for the periods.
	The income tax provision for the years ended December 31, 2014 and 2013 consists of:
		2014			2013
	Current (provision) benefit	$	(302,464	)	$	(4,078,826	)
	Deferred benefit		1,619,321			378,781
	Increase in valuation allowance		(465,069	)		(77,068	)
	Total (provision) benefit	$	851,788		$	(3,777,113	)
	Tax benefit, discontinued operations	$	219,083		$	514,371
	Deferred income tax assets and liabilities as of December 31, 2014 and 2013 are comprised of:
		2014			2013
	Deferred income tax assets:
	Accounts receivable	$	4,512		$	135,983
	Accounts payable		712,683			1,131,070
	Accrued liabilities		260,655			338,901
	Deferred rent and lease incentives		3,856,114			2,353,514
	Stock compensation		—			202,453
	Other assets		54,836			54,836
	Total deferred tax assets		4,888,800			4,216,757
	Valuation allowance		(779,358	)		(314,289	)
	Net deferred tax assets		4,109,442			3,902,468
	Deferred income tax liabilities:
	Fixed assets		(1,267,740	)		(1,158,897	)
	Intangible assets		(1,103,847	)		(1,725,099	)
	Equity investments in affiliates		(861,869	)		(1,330,295	)
	Prepaid and other current assets		(207,976	)		(174,419	)
	Total deferred tax liabilities		(3,441,432	)		(4,388,710	)
	Net deferred tax asset (liability)	$	668,010		$	(486,242	)
	The balance sheet classification of deferred income tax assets (liabilities) at December 31, 2014 and 2013 follows:
		2014			2013
	Current	$	775,248		$	2,118,637
	Long-term		(107,238	)		(2,604,879	)
	Total	$	668,010		$	(486,242	)
	The change in the Company’s valuation allowance on deferred tax assets during the years ended December 31, 2014 and 2013 follows:
		2014			2013
	Beginning valuation allowance	$	314,289		$	—
	Reverse acquisition		—			237,221
	Change in valuation allowance		465,069			77,068
	Ending valuation allowance	$	779,358		$	314,289
	The Company’s effective income tax rate for continuing operations differs from the U.S. Federal statutory rate as follows:
		2014			2013
	Federal statutory rate		34	%		34	%
	State		4	%		4	%
	Adjustment to prior year accrual		-23	%		—
	Permanent and other adjustments		-10	%		—
	Changes in valuation allowances		23	%		-1	%
	Noncontrolling		-72	%		16	%
	Impairment of goodwill		—			-79	%
	Impairment of investment		—			-6	%
	Other		2	%		-4	%
	Effective income tax rate		-42	%		-36	%
	The amount of income taxes the Company pays is subject to ongoing examinations by federal and state tax authorities.  To date, there have been no reviews performed by federal or state tax authorities on any of the Company’s previously filed returns.  The Company’s 2008, 2009 and 2011 and later tax returns are still subject to examination.
	At the time of the Foundation reverse acquisition, Graymark had federal and state net operating loss carryforwards in excess of $30 million.  Due to the change of control resulting from the Foundation reverse acquisition, the Company will not be able to utilize the loss carryforwards.

Capital_Structure

Capital Structure	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Capital Structure	Note 13 – Capital Structure
	At the Company’s annual meeting of stockholders held on May 12, 2014, the Company’s stockholders approved an amendment to our amended and restated certificate of incorporation to effect a reverse split of our common stock at a ratio between 1-for-3 to1-for-10 shares.  The Company’s stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected by filing an appropriate amendment to our amended and restated certificate of incorporation.  The Company’s board of directors authorized the ratio of the reverse split and corresponding reduction in authorized shares on December 29, 2014 and effective at the close of business on January 8, 2015, the Company amended its amended and restated certificate of incorporation to effect a 1-for-10 reverse split of our common stock, or the Reverse Split.  The board of directors considered a ratio that would allow us to have a number of outstanding shares to have a sufficient trading volume while considering a stock price that would be consistent with our intension to eventually uplist of our common stock from the OTC Markets QB Tier to a listing on the NYSE MKT exchange, though there can be no assurance that we will ultimately pursue or be successful in seeking to uplist the Company’s common stock on such exchange.  The Board of Directors determined that a ratio of 1-for-10 was the best balance of these and other factors.  The effect of the reverse split reduced the Company’s outstanding common stock shares from 172,638,414 to 17,263,842 shares as of the date of the reverse split.  The accompanying consolidated financial statements give effect to the reverse split as of the first date reported.
	During 2013 in conjunction with the FHE private placement offering, the Company issued 87,000 shares of common stock valued at $435,000 ($5.00 per share).  See Note 10 – Preferred Noncontrolling Interests for additional information.
	During 2013, the Company issued 24,700 shares of common stock as payments for liabilities owed to certain professional service providers.  The shares were valued at $108,537 which represented the fair value of the services provided.

Stock_Options_Grants_and_Warra

Stock Options, Grants and Warrants	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options, Grants and Warrants	Note 14 – Stock Options, Grants and Warrants
	As part of the Foundation Acquisition, the Company has adopted the 2008 Long-Term Incentive Plan (the “Incentive Plan”).  The Incentive Plan consists of three separate stock incentive plans, a Non-Executive Officer Participant Plan, an Executive Officer Participant Plan and a Non-Employee Director Participant Plan.  Except for administration and the category of employees eligible to receive incentive awards, the terms of the Non-Executive Officer Participant Plan and the Executive Officer Participant Plan are identical.  The Non-Employee Director Plan has other variations in terms and only permits the grant of nonqualified stock options and restricted stock awards.  Each incentive award will be pursuant to a written award agreement.  The number of shares of common stock authorized and reserved under the Incentive Plan is 2,000,000.
	The fair value of each option and warrant grant is estimated on the date of grant using the Black-Scholes option pricing model.  The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables.  These variables include the expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends.  Given the Company’s limited trading history and lack of employee option exercise history, the Company has included the assumptions and variables of similar companies in the determination of the actual variables used in the option pricing model.  The Company bases the risk-free interest rate used in the option pricing model on U.S. Treasury zero-coupon issues.  The Company does not anticipate paying any cash dividends in the foreseeable future and therefore an expected dividend yield of zero is used in the option pricing model.
	The assumptions used to value the option and warrant grants are as follows:
			2014			2013
	Expected life (in years)		2.5			2.5 – 5.0
	Volatility		58	%		73 – 76	%
	Risk free interest rate		0.35	%		0.46 – 1.32	%
	Dividend yield		0	%		0	%
	Information with respect to stock options and warrants outstanding follows:
						Average
						Exercise
			Shares			Price
	Outstanding at January 1, 2013		—			$	—
	Reverse acquisition – warrants		857,242				15.4
	Reverse acquisition – options		56,250				13.3
	Granted – warrants		866,364				13.26
	Granted – options		60,000				4.3
	Forfeited – options		(3,750	)			40
	Outstanding at December 31, 2013		1,836,106				12.91
	Granted – warrants		1,500				5
	Forfeited – options		(2,000	)			12.5
	Forfeited – warrants		(229,650	)			15.82
	Outstanding at December 31, 2014		1,605,956				12.5
									Options and Warrants
			Options and Warrants Outstanding						Exercisable
			Shares		Average		Average		Shares	Average
			Outstanding		Remaining		Exercise		Outstanding	Exercise
			at 12/31/14		Life (Years)		Price		At 12/31/14	Price
	Less than $5.00		102,000		4.6		$	4.59	82,000	$	4.66
	$5.01 to $10.00		193,750		3.6			10	193,750		10
	Greater than $10.00		1,310,206		3.9			13.48	1,310,046		13.48
	Total		1,605,956						1,585,796
	The fair value of the 60,000 options issued in 2013 was estimated to be $120,000.  The value of the options is recorded as compensation expense over the requisite service period which equals the vesting period of the options.  Compensation expense related to stock options was approximately $48,000 and $145,000 during 2014 and 2013, respectively.
	Included in the warrants obtained as part of the reverse acquisition were warrants that were issued under a warrant agreement that contains an anti-dilution provision that requires the exercise price and number of shares exercisable under the warrants to be adjusted in certain instances including when the Company issues an equity security at a price less than $15.00.  During 2013, the Company granted 91,365 additional warrants under this provision and adjusted the exercise price from $14.00 to $12.40.  The total amount of money the Company would receive under the exercise of the warrants did not change.
	In conjunction with the Tyche Agreement, the Company issued Tyche and certain Tyche related entities warrants for the purchase of Company’s common stock (the “Tyche Warrants”).  The Tyche Warrants included:
	1	Five year warrants for the purchase of a total of 193,750 shares of the Company’s common stock at a strike price of $10.00 per share;
	2	Seven and one-half year warrants for the purchase of a total of 351,620 shares of the Company’s common stock at a strike price of $13.50 per share; and
	3	Ten year warrants for the purchase of a total of 229,630 shares of the Company’s common stock at a strike price of $16.00 per share.
	The fair value of the Tyche Warrants was estimated to be $936,000.  See Note 11 – Preferred Noncontrolling Interests for additional information on the Tyche Agreement.
	The options and warrants outstanding and options and warrants exercisable as of December 31, 2014 had no intrinsic value.  The intrinsic value is calculated as the difference between the market value and exercise price of the shares.
	Information with respect to the Company’s restricted stock awards follows:
						Weighted
						Average
						Grant Date
	Unvested Restricted Stock Awards		Shares			Fair Value
	Unvested at January 1, 2013		—			$	—
	Reverse acquisition		4,375				11.11
	Granted		23,000				4.9
	Vested		(1,375	)			28.8
	Forfeited		—				—
	Unvested at December 31, 2013		26,000				4.7
	Granted		971,755				3.62
	Vested		(212,415	)			3.71
	Forfeited		(3,000	)			4.9
	Unvested at December 31, 2014		782,340			$	3.62
	During 2014 and 2013, the Company issued 971,755 and 230,000, respectively, restricted stock grant awards to certain key employees.  The fair value of the restricted stock grant awards was approximately $3,518,000 and $113,000, respectively, and was calculated by multiplying the number of restricted shares issued times the closing share price on the date of issuance.  The value of the stock grants is recorded as compensation over the requisite service period which equals vesting period of the stock award.  During 2014 and 2013, the Company recorded compensation expense related to stock grant awards of approximately $1,337,000 and $130,000, respectively.  As of December 31, 2014 and 2013, the Company had unrecognized compensation expense associated with the stock grants, options and warrants of approximately $2,290,000 and $165,000, respectively.

Gains_and_Other_Item

Gains and Other Item	12 Months Ended
	Dec. 31, 2014
Other Income And Expenses [Abstract]
Gains and Other Item	Note 15 – Gains and Other Item
	Gain on forgiveness of debt and gain on sale-leaseback of real estate – On August 30, 2013, the Company, entered into an Agreement of Sale and Purchase (“Purchase Sale Agreement” or “PSA”) with HCRI Texas Properties, Ltd. (“Seller”) and HC REIT and an Agreement in Connection with Assignment and Assumption of PSA (“Assignment Agreement”) with DOC-FSH El Paso Medical Center, LLC (“DOC”) resulting in a gain of $11.1 million (collectively referred to as the “El Paso Real Estate Transaction”) as summarized below:
	Gain on forgiveness of debt		$	7,108,562
	Gain on sale-leaseback of real estate			3,961,277
	Total gain on El Paso Real Estate Transaction		$	11,069,839
	Pursuant to the PSA, the Company agreed to acquire from Seller the real property occupied and certain personal property used by the Company’s subsidiary East El Paso Physicians’ Medical Center, LLC (“EEPPMC”) under a master lease agreement (“Master Lease”) between EEPPMC, Seller and HCN.
	The real property and other consideration covered by the Purchase Sale Agreement includes the hospital (“Hospital”) and medical office building (“MOB”) occupied by EEPPMC, an adjoining parcel of vacant land (“Excess Land”), the HC REIT Note 2, and certain personal property, including medical equipment, owned by Seller and attached to or located in and used in the operation of the Hospital and MOB (“Personal Property”).  The purchase price under the Purchase Agreement was $39,066,428.
	Simultaneous with the execution of the Purchase Sale Agreement, the Company executed the Assignment Agreement with DOC whereby FSHA assigned and DOC assumed all of FSHA’s right, title, interest and obligations in, to and under the Purchase Sale Agreement, except for the Excess Land, HC REIT Note 2 and Personal Property.  The consideration under the Assignment Agreement with DOC was $40,000,000 and was composed of the following:
	1	$39,066,428 which was paid directly to Seller;
	2	$400,000 which was retained by DOC as a security deposit for the performance of EEPPMC’s payment obligations under the Master Lease;
	3	$463,678 which was paid to the Company; and
	4	$69,894 which was paid on behalf of the Company to cover certain legal and closing expenses.
	The estimated excess value of the assets obtained compared to the consideration paid as a result of the PSA and Assignment agreement was $4,027,562.  The Company is in the process of conducting formal valuations of the Excess Land and Personal Property acquired in the transaction and will adjust the gain accordingly based on the results of those evaluations.
	In conjunction with the execution of the PSA and Assignment Agreement, HC REIT agreed to forgive certain liabilities totaling $7,108,562 due to HC REIT from EEPPMC composed of the following:
	1	$714,824 in capital equipment leases net of the write off of the related capital lease assets;
	2	$467,132 in a note (HC REIT Note 1) and related accrued and unpaid interest (HC REIT Note 1 and HC REIT Note 2);
	3	$2,767,905 in unpaid, past due rent on the hospital and MOB;
	4	$3,158,701 in other accrued liabilities related to the hospital and MOB facilities.
	Other Item – On September 30, 2013, the Company entered into an Agreement of Sale and Purchase (“OKC MOB Agreement”) with Foundation Medical Center of Oklahoma City, LLC (“FMC”) pursuant to which the Company agreed to acquire from Seller the real property occupied as the corporate headquarters of FSA and FSHA.
	The real property covered by the OKC MOB Agreement includes an ambulatory surgery center facility owned and operated by a Foundation affiliate called Foundation Surgery Affiliate of Northwest Oklahoma City, LLC.  The remainder of the building is medical office space occupied by a physician group, a sleep lab, a medical infusion company, and the Foundation corporate office.  The building consists of approximately 52,000 square feet.  The purchase price under the Purchase Agreement was $10,588,235.
	Simultaneous with the execution of the OKC MOB Agreement, the Company entered into an Agreement in Connection with Assignment and Assumption of PSA (“OKC MOB Assignment Agreement”) with DOC-GREYMARK HQ OKC MOB, LLC (“OKC DOC”) whereby the Company assigned and OKC DOC assumed, all of the Company’s right, title, interest and obligations in, to and under the OKC MOB Agreement.  The consideration under the OKC MOB Assignment Agreement with OKC DOC was $15,509,500 and was composed of the following:
	1	$10,588,235 which was paid directly to FMC;
	2	$4,885,328 which was paid to the Company; and
	3	$35,937 which was paid on behalf of the Company to cover certain legal and closing expenses.
	Simultaneous with the sale to OKC DOC, the Company executed a 10 year master lease on the building for an annual rent of $1,248,000 with annual escalations of 2%.  The current lease income on the underlying sub-leases is approximately $900,000 per year.  The master lease is an operating lease.  Given the disparity between the annual rent expense under the master lease and the rental income of the underlying sub-leases, the gain on the sale to OKC DOC was treated as a lease incentive and is being recorded on a straight-line basis as a reduction in the rent expense under the master lease.

Real_Estate_Transaction

Real Estate Transaction	12 Months Ended
	Dec. 31, 2014
Real Estate [Abstract]
Real Estate Transaction	Note 16 – Real Estate Transaction
	On March 1, 2014, the Company executed a 15 year master lease on the building occupied by the Company’s hospital subsidiary in San Antonio, Texas for an annual rent of $2.3 million with annual escalations of 3%. The current lease income on the underlying sub-lease is approximately $2.1 million per year which includes the rent paid by FBH SA. The master lease is an operating lease. In conjunction with the master lease and certain other agreements with the landlord, the Company received $4.1 million at the time of the lease. Given the disparity between the annual rent expense under the master lease and the rental income of the underlying sub-lease, the cash received at the execution of the lease was deferred and will be recorded on a straight-line basis as a reduction in the rent expense under the master lease.

Fair_Value_Measurements

Fair Value Measurements

12 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Fair Value Measurements

Note 17 – Fair Value Measurements

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs).  Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs:

•

Level 1 – Fair value based on quoted prices in active markets for identical assets or liabilities.

•

Level 2 – Fair value based on significant directly observable data (other than Level 1 quoted prices) or significant indirectly observable data through corroboration with observable market data. Inputs would normally be (i) quoted prices in active markets for similar assets or liabilities, (ii) quoted prices in inactive markets for identical or similar assets or liabilities or (iii) information derived from or corroborated by observable market data.

•

Level 3 – Fair value based on prices or valuation techniques that require significant unobservable data inputs.  Inputs would normally be a reporting entity’s own data and judgments about assumptions that market participants would use in pricing the asset or liability.

The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement.  Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs.

Recurring Fair Value Measurements:  The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value.  The carrying value of cash held as demand deposits, money market and certificates of deposit, accounts receivable, short-term borrowings, accounts payable and accrued liabilities approximated their fair value.  At December 31, 2014 and 2013, the fair value of the Company’s long-term debt approximated its fair value.  The fair value of the Company’s debt was valued using significant unobservable inputs (Level 3) including discounted cash flow calculations based upon current market rates for similar types of borrowings with maturities consistent with those remaining for the debt being valued..

Nonrecurring Fair Value Measurements:

Reverse Acquisition – During 2013, the Company completed the Foundation reverse acquisition; see Note 4 – Reverse Acquisition for additional information.  The assets acquired and liabilities assumed in the reverse acquisition were recorded at their fair values on the date of acquisition.

El Paso Real Estate Transaction – On August 30, 2013, the Company, entered into an Agreement of Sale and Purchase (“Purchase Sale Agreement” or “PSA”) with HCRI Texas Properties, Ltd. (“Seller”) and HC REIT and an Agreement in Connection with Assignment and Assumption of PSA (“Assignment Agreement”) with DOC-FSH El Paso Medical Center, LLC (“DOC”) to acquire from Seller the real property occupied and certain personal property used by the Company’s subsidiary East El Paso Physicians’ Medical Center, LLC (“EEPPMC”); see Note 16 – Extraordinary Gain for additional information.  The assets acquired as a result of the El Paso Real Estate Transaction were recorded at their fair market value on the date of the transaction.

Goodwill Impairment – On July 22, 2013, the Company determined that an impairment indicator existed related to the Company’s sleep diagnostic business.  As a result, the Company tested goodwill associated with the sleep diagnostic business for impairment. The impairment test resulted in an impairment charge of $21.9 million.

For the reverse acquisition and goodwill impairment, the nonrecurring fair value measurements were developed using significant unobservable inputs (Level 3) using discounted cash flow calculations based upon the Company’s weighted average cost of capital and third-party valuation services.  For the El Paso Real Estate Transaction, a portion of the fair value measurements were developed using significant other observable inputs (Level 2).  The primary valuation technique used was an income methodology based on estimates of forecasted cash flows for each business unit, with those cash flows discounted to present value using rates commensurate with the risks of those cash flows.  Assumptions used were similar to those that would be used by market participants performing valuations of these business units and were based on analysis of current and expected future economic conditions and the updated strategic plan for each business unit.

The Company did not have assets measured at fair value on a nonrecurring basis in 2014.  The fair value measurements for the Company’s assets measured at fair value on a nonrecurring basis as of December 31, 2013 follows:

Total

Quoted

Significant Other Observable Inputs

Significant

Total Gains

Prices in

(Level 2)

Unobservable

(Losses)

Active

Inputs

Markets for

(Level 3)

Identical

Assets

(Level 1)

December 31, 2013:

Foundation reverse acquisition:

Assets

$

7,475,459

$

—

$

—

$

7,475,459

$

(21,864,781

)

Liabilities

(15,401,366

)

—

—

(15,401,366

)

—

El Paso Real Estate Transaction

3,024,550

—

2,573,633

450,917

3,958,122

$

(17,906,659

)

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	Note 18 – Related Party Transactions
	Effective June 1, 2014, the Company’s hospital subsidiary located in El Paso, Texas entered into a sublease agreement with The New Sleep Lab International, Ltd., referred to as New Sleep. New Sleep is controlled by Dr. Robert Moreno, one of our Directors. The sublease with New Sleep calls for monthly rent payments of $8,767 and the sublease expires on November 30, 2018. The space subleased from New Sleep will be sublet to physician partners and casual uses of our hospital and is located in a building that also houses one of our imaging facilities. During the year ended December 31, 2014, the Company incurred approximately $60,300 in lease expense under the terms of the lease.
	As of December 31, 2014, the Company had $0.4 million on deposit at Valliance Bank.  Valliance Bank is controlled by Mr. Roy T. Oliver, one of our greater than 5% shareholders and affiliates.  In addition, the Company was obligated to Valliance Bank under certain notes payable totaling approximately $5.9 million at December 31, 2013.  On June 30, 2014, the notes were paid in full from the proceeds of the SNB Credit facility.  The interest rates on the notes ranged from 5% to 10%.  Non-controlling interests in Valliance Bank are held by Mr. Stanton Nelson, the Company’s chief executive officer and Mr. Joseph Harroz, Jr., a director of the Company.  Mr. Nelson and Mr. Harroz also serve as directors of Valliance Bank.
	The Company has office space subject to a lease agreement with City Place, LLC (“City Place”).   Under the lease agreement, the Company pays monthly rent of $17,970 until June 30, 2014; $0.00 from July 1, 2014 to January 31, 2015 and $17,970 from February 1, 2015 to March 31, 2017 plus additional payments for allocable basic expenses of City Place; the lease expires on March 31, 2017.  Non-controlling interests in City Place are held by Roy T. Oliver, one of the Company’s greater than 5% shareholders and affiliates.  During the year ended December 31, 2014, the Company incurred $145,945 in lease expense under the terms of the lease.  During the period from July 22, 2013 to December 31, 2013, the Company incurred approximately $57,000 in lease expense under the terms of the lease.
	On July 22, 2013, the Company issued Mr. Roy T. Oliver, one of our greater than 5% shareholders and affiliates, 1,797,030 shares of common stock for full satisfaction of debt owed to Mr. Oliver totaling $8,136,390.  The Company previously used the proceeds from the debt to fund its payment obligations to Arvest bank.
	In October 2013, the Company completed a private placement offering of $9,135,000 (see Note 10 – Preferred Noncontrolling Interests for additional information).  The offering was comprised of 87 FHE Units.  Each FHE Unit was offered at $105,000 and entitled the purchase to one (1) Class B membership interest in FHE, valued at $100,000 and 1,000 shares of the Company’s common stock, valued at $5,000.  Mr. Stanton Nelson, the Company’s chief executive officer, purchased 5 FHE Units for $525,000.
	Until September 30, 2013, FHA charged the Company rent for office space and an allocation for shared services, including payroll, legal and support services.  The total rental expense allocation charged to the Company was $211,787 during 2013.
	The Company has entered into agreements with certain of its Affiliate ASCs and hospitals to provide management services.  As compensation for these services, the surgery centers and hospitals are charged management fees which are either fixed or are based on a percentage of the Affiliates cash collected or the Affiliates net revenue.  The percentages range from 2.25% to 6.0%.
	As of December 30, 2014 and December 31, 2013, the Company has obligations of $1.4 million that are owed to FHA and certain real estate subsidiaries and affiliates of FHA related to transactions that occurred prior to the Foundation acquisition in July 2013. The amounts owed to FHA and FHA affiliates are included in other liabilities on the accompanying consolidated balance sheets.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Note 19 – Subsequent Events
	Management evaluated all activity of the Company and concluded that no material subsequent events have occurred that would require recognition in the consolidated financial statements or disclosure in the notes to the consolidated financial statements, except as noted below:
	On January 1, 2015, Foundation Surgery Affiliate of North West Oklahoma City, L.L.C. (“FSAOKC”), in which the Company held a 20% equity interest, agreed to contribute essentially all of its assets other than cash and accounts receivable to Summit Medical Center, LLC (“Summit”) in exchange for a 40% ownership interest in Summit.  Through this transaction the Company obtained an 8% interest in Summit which will be accounted for under the cost method of accounting.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation	Consolidation – The accompanying consolidated financial statements include the accounts of Foundation Healthcare, Inc. and its wholly owned, majority owned and controlled subsidiaries.  All significant intercompany accounts and transactions have been eliminated in consolidation.
	The Company accounts for its investments in Affiliates in which the Company exhibits significant influence, but not control, in accordance with the equity method of accounting.  The Company does not consolidate its equity method investments, but rather measures them at their initial costs and then subsequently adjusts their carrying values through income for their respective shares of the earnings or losses during the period.  The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.
Use of estimates	Use of estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  Actual results could differ from those estimates.
Reclassifications	Reclassifications – Certain amounts presented in prior years have been reclassified to conform to the current year’s presentation.  Such reclassifications had no effect on net loss.
Pro forma income information	Pro forma income information – Prior to July 22, 2013, FSA’s and FSHA’s member had elected to have FSA’s and FSHA’s income taxed as an S Corporation under provisions of the Internal Revenue Code and a similar section of the state income tax law.  Therefore, taxable income or loss is reported to the individual member for inclusion in its tax returns and no provision for income taxes is included in the Company’s consolidated financial statements for periods prior to July 22, 2013.  The pro forma income information provides an adjustment for income tax expense as if FSA and FSHA had been a C Corporation prior to July 22, 2013 at an assumed combined federal and state effective tax rate of 38%, which approximates the calculated statutory tax rates for the periods.
Revenue recognition and accounts receivable	Revenue recognition and accounts receivable – The Company recognizes revenues in the period in which services are performed and charged.  Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows.  Amounts the Company receives for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations, preferred provider organizations and other private insurers are generally less than the Company’s established billing rates.  Additionally, to provide for accounts receivable that could become uncollectible in the future, the Company establishes an allowance for doubtful accounts to reduce the carrying value of such receivables to their estimated net realizable value.  Accordingly, the revenues and accounts receivable reported in the Company’s consolidated financial statements are recorded at the net amount expected to be received.
	During the years ended December 31, 2014 and 2013, the Company’s revenue payor mix was as follows:
		2014				2013
	Medicare and Medicaid		24	%			29	%
	Commercial health insurance payors		67	%			59	%
	Patient self-pay		4	%			5	%
	Management fees from affiliates		5	%			7	%
	Other		5	%			4	%
	Provision for doubtful accounts		(5	%)			(4	%)
Contractual Discounts and Cost Report Settlements	Contractual Discounts and Cost Report Settlements – The Company derives a significant portion of its revenues from Medicare, Medicaid and other payors that receive discounts from its established billing rates.  The Company must estimate the total amount of these discounts to prepare its consolidated financial statements.  The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex and are subject to interpretation and adjustment.  The Company estimates the allowance for contractual discounts on a payor-specific basis given its interpretation of the applicable regulations or contract terms.  These interpretations sometimes result in payments that differ from the Company’s estimates.  Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.  Changes in estimates related to the allowance for contractual discounts affect revenues reported in the Company’s accompanying consolidated statements of operations.
	Cost report settlements under reimbursement agreements with Medicare and Medicaid are estimated and recorded in the period the related services are rendered and are adjusted in future periods as final settlements are determined.  There is a reasonable possibility that recorded estimates will change by a material amount in the near term.  The net cost report settlements due to the Company were approximately $617,955 and $235,000 at December 31, 2014 and 2013, respectively, and are in included in prepaid and other current assets in the accompanying consolidated balance sheets.  We adjusted our cost report estimate by $382,955 during 2014 based on our final filed cost report for 2013 and an estimate of the 2014 cost report. There was no adjustment for estimated cost report settlements in 2013.  The Company’s management believes that adequate provisions have been made for adjustments that may result from final determination of amounts earned under these programs.
	Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation.  The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements.  Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties and exclusion from the Medicare and Medicaid programs.
Provision and Allowance for Doubtful Accounts	Provision and Allowance for Doubtful Accounts – To provide for accounts receivable that could become uncollectible in the future, the Company establishes an allowance for doubtful accounts to reduce the carrying value of such receivables to their estimated net realizable value.  The primary uncertainty lies with uninsured patient receivables and deductibles, co-payments or other amounts due from individual patients.
	The Company has an established process to determine the adequacy of the allowance for doubtful accounts that relies on a number of analytical tools and benchmarks to arrive at a reasonable allowance.  No single statistic or measurement determines the adequacy of the allowance for doubtful accounts.  Some of the analytical tools that the Company utilizes include, but are not limited to, the aging of accounts receivable, historical cash collection experience, revenue trends by payor classification, the status of claims submitted to third party payors, reason codes for declined claims and an assessment of the Company’s ability to address the issue and resubmit the claim and whether a patient is on a payment plan and making payments consistent with that plan.  Accounts receivable are written off after collection efforts have been followed in accordance with the Company’s policies.
	Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values at the time products or services are provided.  Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available, which could have a material impact on the Company’s operating results and cash flows in subsequent periods.  Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.
	The patient and their third party insurance provider typically share in the payment for the Company’s products and services.  The amount patients are responsible for includes co-payments, deductibles, and amounts not covered due to the provider being out-of-network.  Due to uncertainties surrounding deductible levels and the number of out-of-network patients, the Company is not certain of the full amount of patient responsibility at the time of service.  The Company estimates amounts due from patients prior to service and generally collects those amounts prior to service.  Remaining amounts due from patients are then billed following completion of service.
	The activity in the allowances for doubtful accounts for the years ending December 31, 2014 and 2013 follows:
		2014				2013
	Balance at beginning of period	$	4,778,915			$	1,659,337
	Reclassification (to) from contractual allowance		(832,384	)			1,458,737
	Provisions recognized as reduction in revenues		5,118,194				3,755,035
	Write-offs, net of recoveries		(7,323,154	)			(2,094,194	)
	Balance at end of period	$	1,741,571			$	4,778,915
Cash and cash equivalents	Cash and cash equivalents – The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents.  Certificates of deposit with original maturities of more than three months are also considered cash equivalents if there are no restrictions on withdrawing funds from the account.
Restricted Cash	Restricted cash – As of December 31, 2014 and 2013, the Company had restricted cash of approximately $700,000 and $701,000, respectively, included in prepaid and other current assets in the accompanying consolidated balance sheets.  The restricted cash is pledged as collateral against certain debt of the Company.
Receivables from Affiliates	Receivables from Affiliates – Receivables from Affiliates are stated at the amount billed to the Affiliates plus any accrued and unpaid interest.
Supplies inventories	Supplies inventories – Supplies inventories are stated at the lower of cost or market and primarily include operating supplies used in the direct or indirect treatment of patients.  The Company accounts for inventories using the first in–first out method of accounting for substantially all of its inventories.
Property and equipment	Property and equipment – Property and equipment is stated at cost and depreciated using the straight line method to depreciate the cost of various classes of assets over their estimated useful lives.  At the time assets are sold or otherwise disposed of, the cost and accumulated depreciation are eliminated from the asset and depreciation accounts; profits and losses on such dispositions are reflected in current operations.  Fully depreciated assets are written off against accumulated depreciation.  Assets under capital leases are amortized using the straight-line method over the shorter of the estimated useful life of the assets or life of the lease term, excluding any lease renewals, unless the lease renewals are reasonably assured.  Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized.  Expenditures for maintenance and repairs are charged to expense as incurred.
	The estimated useful lives of the Company’s property and equipment are as follows:
	Asset Class		Useful Life
	Furniture and equipment		3 to 7 years
	Equipment under capital leases		3 to 7 years
	Leasehold improvements		5 to 10 years		or remaining lease period, whichever is shorter
Long-lived assets	Long-lived assets – The Company evaluates its long-lived assets for possible impairment whenever circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future cash flows.  Fair value estimates are derived from established market values of comparable assets or internal calculations of estimated future net cash flows.  The Company’s estimates of future cash flows are based on assumptions and projections it believes to be reasonable and supportable.  The Company’s assumptions take into account revenue and expense growth rates, patient volumes, changes in payor mix and changes in legislation and other payor payment patterns.
Goodwill and Intangible Assets	Goodwill and Intangible Assets – Goodwill is not amortized; instead, it is reviewed for impairment annually (in the fourth quarter) or more frequently if indicators of impairment exist or if a decision is made to sell a business.  A significant amount of judgment is involved in determining if an indicator of impairment has occurred.  Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others.  The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill.  Goodwill is allocated among and evaluated for impairment at the reporting unit level.
	The Financial Accounting Standards Board (FASB) guidance on testing goodwill for impairment provides an entity the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that the estimated fair value of a reporting unit is less than its carrying amount.  If an entity elects to perform a qualitative assessment and determines that an impairment is more likely than not, the entity is then required to perform the existing two-step quantitative impairment test (described below), otherwise no further analysis is required.  An entity also may elect not to perform the qualitative assessment and, instead, proceed directly to the two-step quantitative impairment test.  The ultimate outcome of the goodwill impairment review for a reporting unit should be the same whether an entity chooses to perform the qualitative assessment or proceeds directly to the two-step quantitative impairment test.
	The Company evaluates goodwill for impairment at least on an annual basis and more frequently if certain indicators are encountered.  Goodwill is to be tested at the reporting unit level, defined as an ASC or hospital (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount, including goodwill.  If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired.  The Company completed its annual impairment test as of December 31, 2014, and determined that goodwill was not impaired.
	Intangible assets other than goodwill which include customer relationships, customer files, covenants not to compete, trademarks and payor contracts are amortized over their estimated useful lives using the straight line method.  The remaining lives range from three to five years.  The Company evaluates the recoverability of identifiable intangible asset whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable.
Noncontrolling Interests	Noncontrolling Interests – Noncontrolling interests in the results of operations of consolidated subsidiaries represents the noncontrolling shareholders’ share of the income or loss of the various consolidated subsidiaries.  The noncontrolling interests in the consolidated balance sheet reflect the original investment by these noncontrolling shareholders in these consolidated subsidiaries, along with their proportional share of the earnings or losses of these subsidiaries less distributions made to these noncontrolling interest holders.
Legal Issues	Legal Issues – For asserted claims and assessments, liabilities are recorded when an unfavorable outcome of a matter is deemed to be probable and the loss is reasonably estimable.  Management determines the likelihood of an unfavorable outcome based on many factors such as the nature of the matter, available defenses and case strategy, progress of the matter, views and opinions of legal counsel and other advisors, applicability and success of appeals processes, and the outcome of similar historical matters, among others.  Once an unfavorable outcome is deemed probable, management weighs the probability of estimated losses, and the most reasonable loss estimate is recorded.  If an unfavorable outcome of a matter is deemed to be reasonably possible, then the matter is disclosed and no liability is recorded.  With respect to unasserted claims or assessments, management must first determine that the probability that an assertion will be made is likely, then, a determination as to the likelihood of an unfavorable outcome and the ability to reasonably estimate the potential loss is made.  Legal matters are reviewed on a continuous basis or sooner if significant changes in matters have occurred to determine if a change in the likelihood of an unfavorable outcome or the estimate of a loss is necessary.
Concentration of credit risk	Concentration of credit risk – The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits.  The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk.  As of December 31, 2014 and 2013, the Company had cash deposits in excess of FDIC limits of $1.8 million and $3.4 million, respectively.
Advertising Costs	Advertising Costs – Advertising costs are expensed as incurred.  Advertising expense for 2014 and 2013, included in continuing operations, was approximately $312,000 and $244,000, respectively.
Acquisition Costs	Acquisition Costs – Acquisition costs are charged directly to expense when incurred.
Income Taxes	Income Taxes – The Company recognizes deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect of deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  In the event the Company determines that the deferred tax assets will not be realized in the future, the valuation adjustment to the deferred tax assets is charged to earnings in the period in which the Company makes such a determination.
	The Company uses a two-step process to evaluate a tax position.  The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position.  The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements.  A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.
	Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.  Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met.  The Company reports tax-related interest and penalties as a component of income tax expense.
	Based on all known facts and circumstances and current tax law, the Company believes that the total amount of unrecognized tax benefits as of December 31, 2014, is not material to its results of operations, financial condition or cash flows.  The Company also believes that the total amount of unrecognized tax benefits as of December 31, 2014, if recognized, would not have a material effect on its effective tax rate.  The Company further believes that there are no tax positions for which it is reasonably possible, based on current tax law and policy that the unrecognized tax benefits will significantly increase or decrease over the next 12 months producing, individually or in the aggregate, a material effect on the Company’s results of operations, financial condition or cash flows.
Loss per share	Loss per share – Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period.  Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted during the period.  Dilutive securities having an anti-dilutive effect on diluted earnings (loss) per share are excluded from the calculation.
	The dilutive potential common shares on options and warrants are calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all options and warrants are used to repurchase common stock at market value.  The amount of shares remaining after the proceeds are exhausted represents the potential dilutive effect of the securities.
	The following securities were not included in the computation of diluted earnings (loss) per share from continuing operations or discontinued operations as their effect would be anti-dilutive:
			2014		2013
	Stock options and warrants		1,622,796		1,836,106
	During 2014, management determined that the Company had incorrectly reflected the historical common stock shares attributable to Foundation and the common stock shares issued in the reverse acquisition.  As a result, the Company has restated its previously reported net income (loss) per share the year ended December 31, 2013 in order to correct certain previously reported amounts.  The restatement had no change on the ending number of common shares outstanding at December 31, 2013, but it did change the weighted average number of common and diluted outstanding shares used to calculate earnings per common share.  The restatement had no impact on assets, liabilities, total deficit or net income (loss) attributable to Foundation Healthcare common stock.
	The financial information included in the accompanying consolidated financial statements and notes thereto reflect the effects of the corrections described in the preceding paragraph.  The following tables set forth the correction of the individual affected line items in the accompanying consolidated financial statements:
			Year Ended December 31, 2013
			As Previously
			Reported				Correction			Restated
	Earnings per common share (basic and diluted):
	Net loss from continuing operations attributable to Foundation Healthcare common stock							(0.24
			$	(1.20	)		$		)	$	(1.44	)
	Loss from discontinued operations			(0.05	)			(0.01	)		(0.06	)
	Net loss per share attributable to Foundation Healthcare common stock		$		)			(0.25
				(1.25			$		)	$	(1.50	)
	Weighted average number of common and diluted shares outstanding							(2,657,727
				16,293,013					)		13,635,286
	Pro forma basic and diluted net loss per share		$	(1.26	)		$	(0.25	)	$	(1.51	)
Stock options	Stock options – The Company accounts for its stock option grants using the modified prospective method.  Under the modified prospective method, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period.
Recently Adopted and Recently Issued Accounting Guidance	Recently Adopted and Recently Issued Accounting Guidance
	Adopted Guidance
	On January 2014, the Company adopted changes issued by the FASB to the accounting for obligations resulting from joint and several liability arrangements.  These changes require an entity to measure such obligations for which the total amount of the obligation is fixed at the reporting date as the sum of (i) the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors, and (ii) any additional amount the reporting entity expects to pay on behalf of its co-obligors.  An entity will also be required to disclose the nature and amount of the obligation as well as other information about those obligations.  Examples of obligations subject to these requirements are debt arrangements and settled litigation and judicial rulings.  The adoption of these changes had no impact on the Company’s consolidated financial statements, as the Company does not currently have any such arrangements.
	On January 2014, the Company adopted changes issued by the FASB to the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.  These changes require an entity to present an unrecognized tax benefit as a liability in the financial statements if (i) a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position, or (ii) the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset to settle any additional income taxes that would result from the disallowance of a tax position.  Otherwise, an unrecognized tax benefit is required to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward.  Previously, there was diversity in practice as no explicit guidance existed.  These changes become effective for the Company on January 1, 2014. The adoption of these changes did not have a significant impact on the Company’s consolidated financial statements.
	Issued Guidance
	In April 2014, the FASB issued changes to the reporting of discontinued operations and disclosures of disposals of components of an entity. The amendments change the criteria for reporting discontinued operations while enhancing disclosures in this area. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Additionally, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income and expenses of discontinued operations. The amendments are effective prospectively for all disposals (or classifications as held for sale) of components of an entity, and for all businesses that, on acquisition, are classified as held for sale that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The Company is currently evaluating the new guidance to determine the impact it may have to its consolidated financial statements.
	In May 2014, the FASB issued changes to the recognition of revenue from contracts with customers. These changes created a comprehensive framework for all entities in all industries to apply in the determination of when to recognize revenue, and, therefore, supersede virtually all existing revenue recognition requirements and guidance. This framework is expected to result in less complex guidance in application while providing a consistent and comparable methodology for revenue recognition. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this principle, an entity should apply the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract(s), (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract(s), and (v) recognize revenue when, or as, the entity satisfies a performance obligation. These changes become effective for the Company on January 1, 2017. Management is currently evaluating the potential impact of these changes on the Company’s consolidated financial statements.
	In August 2014, the FASB issued changes to the disclosure of uncertainties about an entity’s ability to continue as a going concern. Under GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Even if an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. Because there is no guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related note disclosures, there is diversity in practice whether, when, and how an entity discloses the relevant conditions and events in its financial statements. As a result, these changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. These changes become effective for the Company for the 2016 annual period. Management has determined that the adoption of these changes will not have an impact on the Company’s consolidated financial statements. Subsequent to adoption, this guidance will need to be applied by management at the end of each annual period and interim period therein to determine what, if any, impact there will be on the consolidated financial statements in a given reporting period.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Revenue Payor Mix	During the years ended December 31, 2014 and 2013, the Company’s revenue payor mix was as follows:
		2014				2013
	Medicare and Medicaid		24	%			29	%
	Commercial health insurance payors		67	%			59	%
	Patient self-pay		4	%			5	%
	Management fees from affiliates		5	%			7	%
	Other		5	%			4	%
	Provision for doubtful accounts		(5	%)			(4	%)
Allowance for Doubtful Accounts	The activity in the allowances for doubtful accounts for the years ending December 31, 2014 and 2013 follows:
		2014				2013
	Balance at beginning of period	$	4,778,915			$	1,659,337
	Reclassification (to) from contractual allowance		(832,384	)			1,458,737
	Provisions recognized as reduction in revenues		5,118,194				3,755,035
	Write-offs, net of recoveries		(7,323,154	)			(2,094,194	)
	Balance at end of period	$	1,741,571			$	4,778,915
Estimated Useful Lives of Property and Equipment	The estimated useful lives of the Company’s property and equipment are as follows:
	Asset Class		Useful Life
	Furniture and equipment		3 to 7 years
	Equipment under capital leases		3 to 7 years
	Leasehold improvements		5 to 10 years		or remaining lease period, whichever is shorter
Securities Not Included in Computation of Diluted Earnings (Loss) Per Share from Continuing or Discontinued Operations	The following securities were not included in the computation of diluted earnings (loss) per share from continuing operations or discontinued operations as their effect would be anti-dilutive:
			2014		2013
	Stock options and warrants		1,622,796		1,836,106
Accompanying Consolidated Financial Statements	The financial information included in the accompanying consolidated financial statements and notes thereto reflect the effects of the corrections described in the preceding paragraph.  The following tables set forth the correction of the individual affected line items in the accompanying consolidated financial statements:
			Year Ended December 31, 2013
			As Previously
			Reported				Correction			Restated
	Earnings per common share (basic and diluted):
	Net loss from continuing operations attributable to Foundation Healthcare common stock							(0.24
			$	(1.20	)		$		)	$	(1.44	)
	Loss from discontinued operations			(0.05	)			(0.01	)		(0.06	)
	Net loss per share attributable to Foundation Healthcare common stock		$		)			(0.25
				(1.25			$		)	$	(1.50	)
	Weighted average number of common and diluted shares outstanding							(2,657,727
				16,293,013					)		13,635,286
	Pro forma basic and diluted net loss per share		$	(1.26	)		$	(0.25	)	$	(1.51	)

Reverse_Acquisition_Tables

Reverse Acquisition (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Preliminary and Final Purchase Allocation for Reverse Acquisition	The preliminary and final purchase allocations for the reverse acquisition are as follows:
			Preliminary			Final
	Cash and cash equivalents		$	68,170		$	68,170
	Accounts receivable		249,333			249,333
	Current assets from discontinued operations		1,773,471			1,360,143
	Other current assets		198,977			198,976
	Total current assets		2,289,951			1,876,622
	Property and equipment		647,862			1,389,169
	Intangible assets		3,800,000			2,733,000
	Goodwill		20,847,608			21,864,781
	Other assets from discontinued operations		295,542			1,224,140
	Other assets		12,753			252,528
	Total assets acquired		27,893,716			29,340,240
	Liabilities assumed:
	Accounts payable and accrued liabilities		2,501,877			2,899,823
	Short term debt		2,000,000			2,000,000
	Current portion of long-term debt		714,711			714,711
	Current liabilities from discontinued operations		7,812,192			7,375,521
	Total current liabilities		13,028,780			12,990,055
	Long-term debt, net of current portion		742,385			742,385
	Other liabilities from discontinued operations		174,509			305,969
	Other liabilities		575,000			1,362,957
	Total liabilities assumed		14,520,674			15,401,366
	Net assets acquired		$	13,373,042		$	13,938,874
Acquisition Revenue and Earnings of Combined Entity Reverse Acquisition	The amounts of acquisition revenues and earnings included in the Company’s consolidated statements of operations for the year ended December 31, 2013, and the revenue and earnings of the combined entity had the reverse acquisition date for Graymark been January 1, 2013 are as follows:
					Loss From						Attributable to Foundation
		Revenue			Continuing Operations			Net Loss			Net Loss			Net Loss
														Per Share
	Actual:
	From 7/22/2013 to12/31/2013	$	968,729		$	(23,413,107	)	$	(24,995,058	)	$	(24,995,058	)
	Supplemental Pro Forma:
	From 1/1/2013 to 12/31/2013	$	94,514,058		$	(24,733,907	)	$	(19,402,769	)	$	(23,616,628	)	$	(1.73	)

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Activity in Acquired Accruals for Restructuring Charges Established for Lease Termination and Other Exit Costs	For the years ended December 31, 2014 and 2013, the activity in the acquired accruals for restructuring charges established for lease termination and other exit costs were as follows
			Lease Termination Cost				Other Exit Cost			Total
	Acquired balance at July 22, 2013		$	335,028			$	140,542		$	475,570
	Adjustments			(172,685	)			—			(172,685	)
	Cash Payments			(84,108	)			(140,542	)		(224,650	)
	Balance at December 31, 2013			78,235				—			78,235
	Adjustments			102,761				—			102,761
	Cash Payments			(70,575	)			—			(70,575	)
	Balance at December 31, 2014		$	110,421			$	—		$	110,421
Operating Results and Balance Sheet Items of Discontinued Operations	The operating results of the discontinued sleep diagnostic and therapy locations and the Company’s other discontinued operations for the year ended December 31, 2014 and from July 22, 2013 to December 31, 2013 are summarized below:
			2014				July 22 to
							December 31,
							2013
	Revenue		$	123,728			$	877,362
	Loss before taxes		$	(576,535	)		$	(1,353,609	)
	Income tax benefit			219,083				514,371
	Loss from discontinued operations, net of tax		$	(357,452	)		$	(839,238	)
	The balance sheet items for discontinued operations as of December 31, 2014 and 2013 are summarized below:
		2014				2013
	Cash and cash equivalents	$	8,148			$	49,252
	Accounts receivable, net of allowances		—				222,943
	Inventories		—				1,893
	Other current assets		334,293				244,541
	Total current assets		342,441				518,629
	Fixed assets, net		165,285				426,228
	Other assets		—				150,000
	Total non-current assets		165,285				576,228
	Total assets	$	507,726			$	1,094,857
	Payables and accrued liabilities	$	839,791			$	1,557,771
	Short-term debt		—				3,994,932
	Current portion of long-term debt		—				67,994
	Total current liabilities		839,791				5,620,697
	Long-term debt, net of current portion		—				9,969
	Total liabilities	$	839,791			$	5,630,666
Discontinued Operations
Schedule of Borrowings and Capital Lease Obligations	The Company’s borrowings and capital lease obligations included in discontinued operations as of December 31, 2014 and 2013 are as follows:
			2014				2013
	Short-term debt
	Arvest Bank		$	—			$	3,994,932
	Long-term Debt
	Sleep center notes payable			—				28,723
	Equipment capital leases			—				49,389
	Total			—				78,112
	Less: Current portion of long term debt			—				(68,143	)
	Long term debt		$	—			$	9,969

Equity_Investments_in_Affiliat1

Equity Investments in Affiliates (Tables)	12 Months Ended
	Dec. 31, 2014
Investments In And Advances To Affiliates Schedule Of Investments [Abstract]
Summary of Equity Investments and Ownership Interests	The Company invests in non-majority interests in its Affiliates.  The Company’s equity investments and respective ownership interest as of December 31, 2014 and 2013 are as follows:
				Ownership %
	Affiliate	Location		2014				2013
	Surgical Hospitals:
	Grayson County Physicians Property, LLC	Sherman, TX			20	%			20	%
	Houston Orthopedic Hospital, LLC	Houston, TX			20	%			20	%
	ASCs:
	Foundation Surgery Affiliate of Nacogdoches, LLP	Nacogdoches, TX			13	%			13	%
	Kirby Glenn Surgery Center	Houston, TX			10	%			10	%
	Park Ten Surgery Center	Houston, TX			10	%			10	%
	Foundation Surgery Affiliate of Middleburg Heights, LLC	Middleburg Heights, OH			10	%			10	%
	Foundation Surgery Affiliate of Huntingdon Valley, LP	Huntingdon Valley, PA			20	%			20	%
	New Jersey Surgery Center, LLC	Mercerville, NJ			10	%			10	%
	Foundation Surgery Affiliate of Northwest Oklahoma City, LLC	Oklahoma City, OK			20	%			20	%
	Metropolitan Medial Partners, LLC ("Chevy Chase")	Chevy Chase, MD			0	%			18	%
	Cumberland Valley Surgery Center, LLC	Hagerstown, MD			32	%			32	%
	Frederick Surgical Center, LLC	Frederick, MD			20	%			20	%
Summary of Unaudited Results of Operations and Financial Position of Equity Investments in Affiliates	The results of operations and financial position for the years ended and as of December 31, 2014 and 2013, respectively, of the Company’s equity investments in Affiliates are as follows:
		2014				2013
	Net operating revenues	$	93,657,544			$	186,777,871
	Net income	$	22,016,318			$	40,559,684
	Current assets	$	20,145,429			$	44,091,846
	Noncurrent assets		40,297,744				44,668,968
	Total assets	$	60,443,173			$	88,760,814
	Current liabilities	$	13,343,319			$	31,891,679
	Noncurrent liabilities		21,489,753				29,015,316
	Total liabilities	$	34,833,073			$	60,906,995
	Members' equity	$	25,610,100			$	27,853,819

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Summary of Property and Equipment Accompanying Consolidated Balance Sheets	Following are the components of property and equipment included in the accompanying consolidated balance sheets as of December 31, 2014 and 2013:
		2014			2013
	Equipment	$	22,813,790		$	21,799,376
	Equipment under capital lease		7,874,259			4,477,231
	Leasehold improvements		2,703,013			2,231,315
	Land		2,065,000			2,065,000
			35,456,062			30,572,922
	Accumulated depreciation		(21,990,872	)		(18,498,936	)
		$	13,465,190		$	12,073,986

Goodwill_and_Other_Intangibles1

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount Of Goodwill	Changes in the carrying amount of goodwill during the years ended December 31, 2014 and 2013 were as follows:
		2014				2013
	Balance, beginning of year	$	973,927			$	1,154,528
	Reverse acquisition		—				21,864,781
	Impairment charge		—				(21,864,781	)
	Finalization of valuation - Imaging Centers		—				(180,601	)
	Balance, end of year	$	973,927			$	973,927
Changes in Carrying Amount of Intangible Assets	Changes in the carrying amount of intangible assets during the years ended December 31, 2014 and 2013 were as follows:
		Carrying				Accumulated
		Amount				Amortization				Net
	1-Jan-13	$	11,791,500			$	(1,520,642	)		$	10,270,858
	Business Acquisition		2,733,000				—				2,733,000
	Amortization		—				(1,865,237	)			(1,865,237	)
	31-Dec-13		14,524,500				(3,385,879	)			11,138,621
	Amortization		—				(2,058,226	)			(2,058,226	)
	31-Dec-14	$	14,524,500			$	(5,444,105	)		$	9,080,395
Intangible Assets	Intangible assets as of December 31, 2014 and 2013 include the following:
				2014
		Useful		Carrying				Accumulated						2013
		Life (Years)		Value				Amortization				Net		Net
	Management fee contracts	8-Jun		$	3,498,500			$	(2,169,907	)		$	1,328,593	$	1,763,463
	Non-compete	5			2,027,000				(849,667	)			1,177,333		1,583,256
	Physician memberships	7			6,468,000				(2,002,000	)			4,466,000		5,390,000
	Trade Name	5			381,000				(110,962	)			270,038		347,218
	Service Contracts	10			2,150,000				(311,569	)			1,838,431		2,054,684
				$	14,524,500			$	(5,444,105	)		$	9,080,395	$	11,138,621
Amortization Expense for Next Five Years Related to Intangible Assets	Amortization expense for the next five years related to these intangible assets is expected to be as follows:
	Year ended December 31,
	2015	$	2,055,474
	2016		2,055,474
	2017		1,994,629
	2018		1,226,387
	2019		985,000
	Thereafter		763,431

Borrowings_and_Capital_Lease_O1

Borrowings and Capital Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Short-Term Debt Obligations	The Company’s short-term debt obligations as of December 31, 2014 and 2013 are as follows:
		Rate (1)		2014			2013
	Note payable - Legacy			$	—		$	2,814,027
	Note payable - S&H leasing				—			1,865,600
	Note payable - working capital				—			800,000
	Insurance premium financings	3.9 - 4.9%			456,784			101,135
	Note payable - Medicare cost report				—			84,065
	Short-term debt			$	456,784		$	5,664,827
	(1) Effective rate as of December 31, 2014
Schedule of Applicable Margins Rate	The Applicable Margins are as follows:
		Applicable Margin
	Senior Debt Ratio	Revolving Loan	Term Loan
	≥ 2.5x	3.75%	4.25%
	< 2.5x, but ≥ 2.0x	3.25%	3.75%
	< 2.0 x	2.75%	3.25%
Future Maturities of Long-Term Debt	At December 31, 2014, future maturities of long-term debt were as follows:
	Year ended December 31:
	2015	$	5,023,048
	2016		4,781,929
	2017		4,613,541
	2018		4,604,681
	2019		4,625,161
	Thereafter		6,112,407
Continuing Operations
Schedule of Borrowings and Capital Lease Obligations	The Company’s long-term debt and capital lease obligations as of December 31, 2014 and 2013 are as follows:
		Rate (1)				Maturity	2014			2013
						Date
	Senior Lender:
	Note payable		4.40%			Jul. 2021	$	25,750,000		$	—
	Other Lenders:
	Line of credit							—			896,000
	Notes payable - working capital							—			3,715,088
	Note payable - equity investments							—			3,270,427
	Note payable - management agreements							—			640,466
	Note payable - assumption							—			146,857
	Note payable - preferred interest redemption							—			5,100,000
	Note payable - settlements							—			1,189,725
	Note payable - THE							—			311,149
	Notes payable - physician partners							—			103,604
	Notes payable - acquisition							—			99,610
	Capital Lease Obligations	5.5 - 10.7%				Feb. 2015 -		4,010,767			2,477,985
						Dec. 2020
	Total							29,760,767			17,950,911
	Less: Current portion of long-term debt							(5,023,048	)		(7,919,179	)
	Long-term debt						$	24,737,719		$	10,031,732
	(1) Effective rate as of December 31, 2014

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Summary of Future Minimum Lease Payments under Operating Leases	Following is a summary of the future minimum lease payments under operating leases as of December 31, 2014:
	2015	$	11,675,379
	2016		11,760,275
	2017		11,826,286
	2018		11,737,775
	2019		11,431,044
	Thereafter		84,661,254
	Less: Sublease income		(3,457,542	)
	Total	$	139,634,471

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Provision	The income tax provision for the years ended December 31, 2014 and 2013 consists of:
		2014			2013
	Current (provision) benefit	$	(302,464	)	$	(4,078,826	)
	Deferred benefit		1,619,321			378,781
	Increase in valuation allowance		(465,069	)		(77,068	)
	Total (provision) benefit	$	851,788		$	(3,777,113	)
	Tax benefit, discontinued operations	$	219,083		$	514,371
Deferred Income Tax Assets and Liabilities	Deferred income tax assets and liabilities as of December 31, 2014 and 2013 are comprised of:
		2014			2013
	Deferred income tax assets:
	Accounts receivable	$	4,512		$	135,983
	Accounts payable		712,683			1,131,070
	Accrued liabilities		260,655			338,901
	Deferred rent and lease incentives		3,856,114			2,353,514
	Stock compensation		—			202,453
	Other assets		54,836			54,836
	Total deferred tax assets		4,888,800			4,216,757
	Valuation allowance		(779,358	)		(314,289	)
	Net deferred tax assets		4,109,442			3,902,468
	Deferred income tax liabilities:
	Fixed assets		(1,267,740	)		(1,158,897	)
	Intangible assets		(1,103,847	)		(1,725,099	)
	Equity investments in affiliates		(861,869	)		(1,330,295	)
	Prepaid and other current assets		(207,976	)		(174,419	)
	Total deferred tax liabilities		(3,441,432	)		(4,388,710	)
	Net deferred tax asset (liability)	$	668,010		$	(486,242	)
Balance Sheet Classification of Deferred Income Tax Assets and Liabilities	The balance sheet classification of deferred income tax assets (liabilities) at December 31, 2014 and 2013 follows:
		2014			2013
	Current	$	775,248		$	2,118,637
	Long-term		(107,238	)		(2,604,879	)
	Total	$	668,010		$	(486,242	)
Change in Valuation Allowance on Deferred Tax Assets	The change in the Company’s valuation allowance on deferred tax assets during the years ended December 31, 2014 and 2013 follows:
		2014			2013
	Beginning valuation allowance	$	314,289		$	—
	Reverse acquisition		—			237,221
	Change in valuation allowance		465,069			77,068
	Ending valuation allowance	$	779,358		$	314,289
Effective Income Tax Rate	The Company’s effective income tax rate for continuing operations differs from the U.S. Federal statutory rate as follows:
		2014			2013
	Federal statutory rate		34	%		34	%
	State		4	%		4	%
	Adjustment to prior year accrual		-23	%		—
	Permanent and other adjustments		-10	%		—
	Changes in valuation allowances		23	%		-1	%
	Noncontrolling		-72	%		16	%
	Impairment of goodwill		—			-79	%
	Impairment of investment		—			-6	%
	Other		2	%		-4	%
	Effective income tax rate		-42	%		-36	%

Stock_Options_Grants_and_Warra1

Stock Options, Grants and Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Assumptions used to Value Option and Warrant Grants	The assumptions used to value the option and warrant grants are as follows:
		2014			2013
	Expected life (in years)	2.5			2.5 – 5.0
	Volatility	58	%		73 – 76	%
	Risk free interest rate	0.35	%		0.46 – 1.32	%
	Dividend yield	0	%		0	%
Information with Respect to Stock Options and Warrants Outstanding	Information with respect to stock options and warrants outstanding follows:
					Average
					Exercise
		Shares			Price
	Outstanding at January 1, 2013	—			$	—
	Reverse acquisition – warrants	857,242				15.4
	Reverse acquisition – options	56,250				13.3
	Granted – warrants	866,364				13.26
	Granted – options	60,000				4.3
	Forfeited – options	(3,750	)			40
	Outstanding at December 31, 2013	1,836,106				12.91
	Granted – warrants	1,500				5
	Forfeited – options	(2,000	)			12.5
	Forfeited – warrants	(229,650	)			15.82
	Outstanding at December 31, 2014	1,605,956				12.5
								Options and Warrants
		Options and Warrants Outstanding						Exercisable
		Shares		Average		Average		Shares	Average
		Outstanding		Remaining		Exercise		Outstanding	Exercise
		at 12/31/14		Life (Years)		Price		At 12/31/14	Price
	Less than $5.00	102,000		4.6		$	4.59	82,000	$	4.66
	$5.01 to $10.00	193,750		3.6			10	193,750		10
	Greater than $10.00	1,310,206		3.9			13.48	1,310,046		13.48
	Total	1,605,956						1,585,796
Information with respect to Restricted Stock Awards	Information with respect to the Company’s restricted stock awards follows:
					Weighted
					Average
					Grant Date
	Unvested Restricted Stock Awards	Shares			Fair Value
	Unvested at January 1, 2013	—			$	—
	Reverse acquisition	4,375				11.11
	Granted	23,000				4.9
	Vested	(1,375	)			28.8
	Forfeited	—				—
	Unvested at December 31, 2013	26,000				4.7
	Granted	971,755				3.62
	Vested	(212,415	)			3.71
	Forfeited	(3,000	)			4.9
	Unvested at December 31, 2014	782,340			$	3.62

Gains_and_Other_Item_Tables

Gains and Other Item (Tables)	12 Months Ended
	Dec. 31, 2014
Other Income And Expenses [Abstract]
Gain on forgiveness of debt and gain on sale-leaseback of real estate	Gain on forgiveness of debt and gain on sale-leaseback of real estate
	Gain on forgiveness of debt	$	7,108,562
	Gain on sale-leaseback of real estate		3,961,277
	Total gain on El Paso Real Estate Transaction	$	11,069,839

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Fair Value Measurements for Assets Measured at Fair Value on Nonrecurring Basis	The fair value measurements for the Company’s assets measured at fair value on a nonrecurring basis as of December 31, 2013 follows:
		Total			Quoted		Significant Other Observable Inputs		Significant			Total Gains
					Prices in		(Level 2)		Unobservable			(Losses)
					Active				Inputs
					Markets for				(Level 3)
					Identical
					Assets
					(Level 1)
	December 31, 2013:
	Foundation reverse acquisition:
	Assets	$	7,475,459		$	—	$	—	$	7,475,459		$	(21,864,781	)
	Liabilities		(15,401,366	)		—		—		(15,401,366	)		—
	El Paso Real Estate Transaction		3,024,550			—		2,573,633		450,917			3,958,122
												$	(17,906,659	)

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	12-May-14	Jan. 08, 2015	Dec. 31, 2012
Basis of Presentation [Line Items]
Accumulated deficit	($37,265,044)	($35,171,315)
Adjusted working capital deficit	200,000
Redemption payments, payable to preferred noncontrolling interest holders	1,700,000
Net loss attributable to Foundation HealthCare common stock	-2,093,729	-20,426,627
Cash flow from operating activities from continuing operations	2,934,353	7,344,506
Cash and cash equivalents	2,860,025	4,212,076			3,037,067
Common stock, shares outstanding	17,263,842	16,383,489
Maximum
Basis of Presentation [Line Items]
Common stock reverse split, conversion ratio			0.33
Minimum
Basis of Presentation [Line Items]
Common stock reverse split, conversion ratio			0.1
Subsequent Event
Basis of Presentation [Line Items]
Common stock reverse split, conversion ratio				0.1
Common stock, shares outstanding				17,263,842
Before Reverse Stock Split
Basis of Presentation [Line Items]
Common stock, shares outstanding	172,638,414
Senior Lender
Basis of Presentation [Line Items]
Line of Credit	$2,500,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jul. 22, 2013	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]
Effect of reclassifications on net loss		$0
Federal and state effective tax rate	38.00%	-42.00%	-36.00%
Adjustments for cost report settlements		382,955	0
Likelihood percentage for impairment minimum		50.00%
Cash deposits in excess of FDIC limits		1,800,000	3,400,000
Advertising expense		312,000	244,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives		3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives		5 years
Prepaid and Other Current Assets
Summary Of Significant Accounting Policies [Line Items]
Cost settlements adjustment amount		617,955	235,000
Restricted cash		$700,000	$701,000

Revenue_Payor_Mix_Detail

Revenue Payor Mix (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Medicare and Medicaid
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Revenues by payer type sales revenue percentage	24.00%	29.00%
Commercial health insurance payors
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Revenues by payer type sales revenue percentage	67.00%	59.00%
Patient self-pay
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Revenues by payer type sales revenue percentage	4.00%	5.00%
Management fees from affiliates
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Revenues by payer type sales revenue percentage	5.00%	7.00%
Other
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Revenues by payer type sales revenue percentage	5.00%	4.00%
Provision for doubtful accounts
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Revenues by payer type sales revenue percentage	-5.00%	-4.00%

Allowance_for_Doubtful_Account

Allowance for Doubtful Accounts (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Allowance For Doubtful Accounts Receivable Rollforward
Balance at beginning of period	$4,778,915	$1,659,337
Reclassification (to) from contractual allowance	-832,384	1,458,737
Provisions recognized as reduction in revenues	5,118,194	3,755,035
Write-offs, net of recoveries	-7,323,154	-2,094,194
Balance at end of period	$1,741,571	$4,778,915

Estimated_Useful_Lives_of_Prop

Estimated Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2014
Furniture and equipment | Minimum
Property Plant And Equipment Estimated Useful Lives [Line Items]
Property, plant and equipment, useful life	3 years
Furniture and equipment | Maximum
Property Plant And Equipment Estimated Useful Lives [Line Items]
Property, plant and equipment, useful life	7 years
Equipment capital leases | Minimum
Property Plant And Equipment Estimated Useful Lives [Line Items]
Property, plant and equipment, useful life	3 years
Equipment capital leases | Maximum
Property Plant And Equipment Estimated Useful Lives [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold improvements
Property Plant And Equipment Estimated Useful Lives [Line Items]
Property, plant and equipment, useful life	5 to 10 years or remaining lease period, whichever is shorter

Securities_Not_Included_in_Com

Securities Not Included in Computation of Diluted Earnings (Loss) Per Share from Continuing or Discontinued Operations (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Stock options and warrants	1,622,796	1,836,106

Accompanying_Consolidated_Fina

Accompanying Consolidated Financial Statements (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share Basic [Line Items]
Net loss from continuing operations attributable to Foundation Healthcare common stock	($0.10)	($1.44)
Loss from discontinued operations, net of tax	($0.02)	($0.06)
Net loss per share attributable to Foundation Healthcare common stock	($0.12)	($1.50)
Weighted average number of common and diluted shares outstanding	17,080,451	13,635,286
As Previously Reported
Earnings Per Share Basic [Line Items]
Net loss from continuing operations attributable to Foundation Healthcare common stock		($1.20)
Loss from discontinued operations, net of tax		($0.05)
Net loss per share attributable to Foundation Healthcare common stock		($1.25)
Weighted average number of common and diluted shares outstanding		16,293,013
Correction
Earnings Per Share Basic [Line Items]
Net loss from continuing operations attributable to Foundation Healthcare common stock		($0.24)
Loss from discontinued operations, net of tax		($0.01)
Net loss per share attributable to Foundation Healthcare common stock		($0.25)
Weighted average number of common and diluted shares outstanding		-2,657,727
Pro Forma
Earnings Per Share Basic [Line Items]
Net loss per share attributable to Foundation Healthcare common stock		($1.51)
Pro Forma | As Previously Reported
Earnings Per Share Basic [Line Items]
Net loss per share attributable to Foundation Healthcare common stock		($1.26)
Pro Forma | Correction
Earnings Per Share Basic [Line Items]
Net loss per share attributable to Foundation Healthcare common stock		($0.25)

Reverse_Acquisition_Additional

Reverse Acquisition - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2013	Jul. 22, 2013	Dec. 31, 2014
Business Acquisition [Line Items]
Common stock, shares issued	16,383,489		17,263,842
Common stock value	$1,638		$1,726
Fair value of consideration issued in reverse acquisition	2,339,905
Incurred expenses	506,000
Arvest Loan Participation
Business Acquisition [Line Items]
Common stock, shares issued		1,333,333
Common stock value		6,000,000
Roy T. Oliver
Business Acquisition [Line Items]
Common stock, shares issued		1,797,030
Common stock value		8,136,390
Percentage of ownership in shareholders and affiliates		5.00%
Foundation Health Care Affiliates, LLC
Business Acquisition [Line Items]
Number of shares issued in connection with acquisition		11,450,000
Promissory note		2,000,000
Assumed certain liabilities and obligations		2,000,000
Fair value of consideration issued in reverse acquisition		$13,900,000

Preliminary_and_Final_Purchase

Preliminary and Final Purchase Allocations for Reverse Acquisition (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 22, 2013
Assets acquired
Goodwill	$973,927	$973,927	$1,154,528
Foundation Health Care Affiliates, LLC
Liabilities assumed:
Total liabilities assumed				2,000,000
Graymark | Foundation Health Care Affiliates, LLC
Assets acquired
Cash and cash equivalents	68,170
Accounts receivable	249,333
Current assets from discontinued operations	1,360,143
Other current assets	198,976
Total current assets	1,876,622
Property and equipment	1,389,169
Intangible assets	2,733,000
Goodwill	21,864,781
Other assets from discontinued operations	1,224,140
Other assets	252,528
Total assets acquired	29,340,240
Liabilities assumed:
Accounts payable and accrued liabilities	2,899,823
Short term debt	2,000,000
Current portion of long-term debt	714,711
Current liabilities from discontinued operations	7,375,521
Total current liabilities	12,990,055
Long-term debt, net of current portion	742,385
Other liabilities from discontinued operations	305,969
Other liabilities	1,362,957
Total liabilities assumed	15,401,366
Net assets acquired	13,938,874
Graymark | As Previously Reported | Foundation Health Care Affiliates, LLC
Assets acquired
Cash and cash equivalents	68,170
Accounts receivable	249,333
Current assets from discontinued operations	1,773,471
Other current assets	198,977
Total current assets	2,289,951
Property and equipment	647,862
Intangible assets	3,800,000
Goodwill	20,847,608
Other assets from discontinued operations	295,542
Other assets	12,753
Total assets acquired	27,893,716
Liabilities assumed:
Accounts payable and accrued liabilities	2,501,877
Short term debt	2,000,000
Current portion of long-term debt	714,711
Current liabilities from discontinued operations	7,812,192
Total current liabilities	13,028,780
Long-term debt, net of current portion	742,385
Other liabilities from discontinued operations	174,509
Other liabilities	575,000
Total liabilities assumed	14,520,674
Net assets acquired	$13,373,042

Acquisition_Revenue_and_Earnin

Acquisition Revenue and Earnings of Combined Entity Reverse Acquisition (Detail) (USD $)	12 Months Ended		6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013
Business Acquisition [Line Items]
Revenue	$101,858,149	$87,207,659
Income (loss) from continuing operations	2,872,015	-14,219,869
Net Loss	2,514,563	-15,059,107
Net Income (Loss) Attributable to Foundation	-1,312,876	-19,404,524
Net Income (Loss) per Share Attributable to Foundation	($0.12)	($1.50)
Graymark
Business Acquisition [Line Items]
Revenue			968,729
Income (loss) from continuing operations			-23,413,107
Net Loss			-24,995,058
Net Income (Loss) Attributable to Foundation			-24,995,058
Supplemental Pro Forma, Revenues		94,514,058
Supplemental Pro Forma, Loss from Continuing Operations		-24,733,907
Supplemental Pro Forma, Net Loss		-19,402,769
Supplemental Pro Forma, Net Loss Attributable to Foundation		($23,616,628)
Supplemental Pro Forma, Net Loss Per Share Attributable to Foundation		($1.73)

Discontinued_Operations_Additi

Discontinued Operations - Additional Information (Detail) (USD $)	3 Months Ended
	Oct. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Jul. 22, 2013
	Location
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Amount of special charge liability acquired as part of reverse acquisition		$110,421	$78,235	$475,570
Reverse Acquisition
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Amount of special charge liability acquired as part of reverse acquisition		$475,570
Sleep diagnostic locations
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of locations closed or sold	24
Sleep Therapy Business
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of locations closed or sold	5

Activity_in_Acquired_Accruals_

Activity in Acquired Accruals for Restructuring Charges Established for Lease Termination and Other Exit Costs (Detail) (USD $)	5 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Jul. 22, 2013
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Beginning Balance		$78,235	$475,570
Adjustments	-172,685	102,761
Cash Payments	-224,650	-70,575
Ending Balance	78,235	110,421	475,570
Lease Termination Costs
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Beginning Balance		78,235	335,028
Adjustments	-172,685	102,761
Cash Payments	-84,108	-70,575
Ending Balance	78,235	110,421	335,028
Other Exit Costs
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Beginning Balance			140,542
Cash Payments	-140,542
Ending Balance			$140,542

Operating_Results_and_Balance_

Operating Results and Balance Sheet Items of Discontinued Operations (Detail) (USD $)	5 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]
Revenue	$877,362	$123,728
Loss before taxes	-1,353,609	-576,535
Income tax benefit	514,371	219,083	514,371
Loss from discontinued operations, net of tax	-839,238	-357,452	-839,238
Cash and cash equivalents	49,252	8,148	49,252
Accounts receivable, net of allowances	222,943		222,943
Inventories	1,893		1,893
Other current assets	244,541	334,293	244,541
Total current assets	518,629	342,441	518,629
Fixed assets, net	426,228	165,285	426,228
Other assets	150,000		150,000
Total non-current assets	576,228	165,285	576,228
Total assets	1,094,857	507,726	1,094,857
Payables and accrued liabilities	1,557,771	839,791	1,557,771
Short-term debt	3,994,932		3,994,932
Current portion of long-term debt	67,994		67,994
Total current liabilities	5,620,697	839,791	5,620,697
Long-term debt, net of current portion	9,969		9,969
Total liabilities	$5,630,666	$839,791	$5,630,666

Schedule_of_Borrowings_and_Cap

Schedule of Borrowings and Capital Lease Obligations (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Short-term debt	$456,784	$5,664,827
Long-term debt	29,760,767	17,950,911
Less: Current portion of long term debt	-5,023,048	-7,919,179
Long term debt	24,737,719	10,031,732
Discontinued Operations
Debt Instrument [Line Items]
Long-term debt		78,112
Less: Current portion of long term debt		-68,143
Long term debt		9,969
Discontinued Operations | Arvest bank
Debt Instrument [Line Items]
Short-term debt		3,994,932
Discontinued Operations | Sleep center notes payable
Debt Instrument [Line Items]
Long-term debt		28,723
Discontinued Operations | Equipment capital leases
Debt Instrument [Line Items]
Long-term debt		$49,389

Summary_of_Equity_Investments_

Summary of Equity Investments and Ownership Interests (Detail)	Dec. 31, 2014	Dec. 31, 2013
Grayson County Physicians Property LLC | Sherman TX
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	20.00%	20.00%
Houston Orthopedic Hospital LLC | Houston TX
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	20.00%	20.00%
Foundation Surgery Affiliate of Nacogdoches LLP | Nacogdoches TX
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	13.00%	13.00%
Kirby Glen Surgery Center | Houston TX
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	10.00%	10.00%
Park Ten Surgery Center
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	10.00%	10.00%
Foundation Surgery Affiliate of Middleburg Heights LLC | Middleburg Heights OH
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	10.00%	10.00%
Foundation Surgery Affiliate of Huntingdon Valley LP | Huntingdon Valley PA
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	20.00%	20.00%
New Jersey Surgery Center LLC | Mercerville NJ
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	10.00%	10.00%
Foundation Surgery Affiliate of Northwest Oklahoma City LLC | Oklahoma City OK
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	20.00%	20.00%
Metropolitan Medical Partners LLC ("Chevy Chase") | Chevy Chase MD
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	0.00%	18.00%
Cumberland Valley Surgery Center LLC | Hagerstown MD
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	32.00%	32.00%
Frederick Surgical Center LLC | Frederick MD
Investments in and Advances to Affiliates [Line Items]
Equity investments, ownership interest	20.00%	20.00%

Summary_of_Unaudited_Results_o

Summary of Unaudited Results of Operations and Financial Position of Equity Investments in Affiliates (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Investments In And Advances To Affiliates Schedule Of Investments [Abstract]
Net operating revenues	$93,657,544	$186,777,871
Net income	22,016,318	40,559,684
Current assets	20,145,429	44,091,846
Noncurrent assets	40,297,744	44,668,968
Total assets	60,443,173	88,760,814
Current liabilities	13,343,319	31,891,679
Noncurrent liabilities	21,489,753	29,015,316
Total liabilities	34,833,073	60,906,995
Members' equity	$25,610,100	$27,853,819

Equity_Investments_in_Affiliat2

Equity Investments in Affiliates - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Oct. 31, 2014
Schedule Of Equity Method Investments [Line Items]
Company's ownership interest in Chevy Chase, Value		$178,000	$178,000
Impairment of equity investment in affiliate	$1,600,000	$1,640,389
Metropolitan Medical Partners LLC ("Chevy Chase") | Chevy Chase MD
Schedule Of Equity Method Investments [Line Items]
Company's ownership interest in Chevy Chase, percentage	0.00%	18.00%

Summary_of_Property_and_Equipm

Summary of Property and Equipment Accompanying Consolidated Balance Sheets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$35,456,062	$30,572,922
Accumulated depreciation	-21,990,872	-18,498,936
Property and equipment, net	13,465,190	12,073,986
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,813,790	21,799,376
Equipment under capital lease
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,874,259	4,477,231
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,703,013	2,231,315
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$2,065,000	$2,065,000

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Abstract]
Depreciation Expense	$5,550,161	$3,228,009

Changes_in_Carrying_Amount_of_

Changes in Carrying Amount of Goodwill (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jul. 22, 2013	Dec. 31, 2013	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Balance, beginning of year		$1,154,528	$973,927
Reverse acquisition		21,864,781
Impairment charge	-21,900,000	-21,864,781
Finalization of valuation - Imaging Centers		-180,601
Balance, end of year		$973,927	$973,927

Goodwill_and_Other_Intangibles2

Goodwill and Other Intangibles - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Reverse acquisition	$21,864,781

Changes_in_Carrying_Amount_of_1

Changes in Carrying Amount of Intangible Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible asset carrying amount, beginning balance	$14,524,500	$11,791,500
Intangible asset carrying amount, business acquisition		2,733,000
Intangible asset carrying amount, ending balance	14,524,500	14,524,500
Intangible asset accumulated amortization, beginning balance	-3,385,879	-1,520,642
Intangible asset, accumulated amortization	-2,058,226	-1,865,237
Intangible asset accumulated amortization, ending balance	-5,444,105	-3,385,879
Intangible asset beginning balance, net	11,138,621	10,270,858
Intangible asset business acquisition, net		2,733,000
Intangible asset ending balance, net	$9,080,395	$11,138,621

Intangible_Assets_Detail

Intangible Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Finite Lived Intangible Assets [Line Items]
Carrying Value	$14,524,500	$14,524,500	$11,791,500
Accumulated Amortization	-5,444,105	-3,385,879	-1,520,642
Intangible assets, net	9,080,395	11,138,621	10,270,858
Management Fee Contracts
Finite Lived Intangible Assets [Line Items]
Carrying Value	3,498,500
Accumulated Amortization	-2,169,907
Intangible assets, net	1,328,593	1,763,463
Non-compete
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	5 years
Carrying Value	2,027,000
Accumulated Amortization	-849,667
Intangible assets, net	1,177,333	1,583,256
Physician memberships
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	7 years
Carrying Value	6,468,000
Accumulated Amortization	-2,002,000
Intangible assets, net	4,466,000	5,390,000
Trade Name
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	5 years
Carrying Value	381,000
Accumulated Amortization	-110,962
Intangible assets, net	270,038	347,218
Service Contracts
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	10 years
Carrying Value	2,150,000
Accumulated Amortization	-311,569
Intangible assets, net	$1,838,431	$2,054,684
Minimum
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Minimum | Management Fee Contracts
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	6 years
Maximum
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	5 years
Maximum | Management Fee Contracts
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	8 years

Amortization_Expense_for_Next_

Amortization Expense for Next Five Years Related to Intangible Assets (Detail) (USD $)	Dec. 31, 2014
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2015	$2,055,474
2016	2,055,474
2017	1,994,629
2018	1,226,387
2019	985,000
Thereafter	$763,431

Schedule_of_ShortTerm_Debt_Obl

Schedule of Short-Term Debt Obligations (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Short-term Debt [Line Items]
Short-term debt	$456,784		$5,664,827
Note payable - Legacy
Short-term Debt [Line Items]
Short-term debt			2,814,027
Note payable - S&H Leasing
Short-term Debt [Line Items]
Short-term debt			1,865,600
Note payable - working capital
Short-term Debt [Line Items]
Short-term debt			800,000
Insurance premium financings
Short-term Debt [Line Items]
Short-term debt	456,784		101,135
Debt instrument, effective interest rate, minimum	3.90%	[1]
Debt instrument, effective interest rate, maximum	4.90%	[1]
Note Payable Medicare Cost Report
Short-term Debt [Line Items]
Short-term debt			$84,065
[1]	Effective rate as of December 31, 2014

Borrowings_and_Capital_Lease_O2

Borrowings and Capital Lease Obligations - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013	Jun. 30, 2014
Debt Instrument [Line Items]
Long-term debt	$29,760,767		$17,950,911
Permitted merger or acquisition consideration amount	1,000,000
Sale of assets, maximum limit	100,000
Percentage of prepayment on excess cash flow	30.00%
Prepayment on excess cash flow	533,884
Prepayment penalty percentage on term loan prior to first Anniversary	2.00%
Prepayment penalty percentage on term loan after first anniversary	1.50%
Prepayment penalty percentage on term loan after second anniversary	1.00%
Senior debt ratio	176.00%
Senior debt service coverage ratio	207.00%
Adjusted senior debt service coverage ratio	141.00%
Restriction on indebtedness in trade payable, maximum	500,000
Restriction on indebtedness in unsecured debt, maximum	100,000
Amount of judgment triggering default	150,000
Debt default, description	In addition to the general defaults of failure to perform our obligations under the Loan Agreement, events of default also include the occurrence of a change in control, as defined, and the loss of our Medicare or Medicaid certification, collateral casualties, entry of a judgment of $150,000 or more, failure of first liens on collateral and the termination of any of our management agreements that represent more than 10% of our management fees for the preceding 18 month period. In the event of a monetary default, all of our obligations due under the SNB Credit Facility shall become immediately due and payable. In the event of a non-monetary default, we have 10 days or in some cases three days to cure before bankSNB has the right to declare our obligations due under the SNB Credit Facility immediately due and payable.
Term Loan
Debt Instrument [Line Items]
Long-term debt				27,500,000
Debt instrument maturity date	30-Jun-21
Debt instrument applicable margin	4.25%
Term Loan | First Four Quarterly Payments
Debt Instrument [Line Items]
Quarterly principal payment	875,000
Term Loan | Subsequent Quarterly Payments
Debt Instrument [Line Items]
Quarterly principal payment	1,000,000
Revolving Loan
Debt Instrument [Line Items]
Line of credit collateralized				2,500,000
Debt instrument maturity date	30-Jun-16
Debt instrument applicable margin	3.75%
Insurance premium financings
Debt Instrument [Line Items]
Debt instrument, effective interest rate, minimum	3.90%	[1]
Debt instrument, effective interest rate, maximum	4.90%	[1]
Monthly principal and interest payment	$154,064
Minimum
Debt Instrument [Line Items]
Senior debt service coverage ratio	130.00%
Adjusted senior debt service coverage ratio	105.00%
Minimum | Insurance premium financings
Debt Instrument [Line Items]
Debt instrument, maturity month and year	2015-01
Maximum
Debt Instrument [Line Items]
Senior debt ratio	300.00%
Maximum | Insurance premium financings
Debt Instrument [Line Items]
Debt instrument, maturity month and year	2015-10
[1]	Effective rate as of December 31, 2014

Schedule_of_LongTerm_Debt_and_

Schedule of Long-Term Debt and Capital Lease Obligations (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Long Term Debt [Line Items]
Long-term debt	$29,760,767		$17,950,911
Less: Current portion of long term debt	-5,023,048		-7,919,179
Long-term debt, net of current portion	24,737,719		10,031,732
Capital lease obligations
Long Term Debt [Line Items]
Debt instrument, effective interest rate, minimum	5.50%	[1]
Debt instrument, effective interest rate, maximum	10.70%	[1]
Long-term debt	4,010,767		2,477,985
Capital lease obligations | Minimum
Long Term Debt [Line Items]
Debt instrument maturity date	2015-02
Capital lease obligations | Maximum
Long Term Debt [Line Items]
Debt instrument maturity date	2020-12
Senior Lender | Note Payable
Long Term Debt [Line Items]
Debt instrument, effective interest rate	4.40%	[1]
Debt instrument maturity date	2021-07
Long-term debt	25,750,000
Other Lenders | Line of credit
Long Term Debt [Line Items]
Long-term debt			896,000
Other Lenders | Note payable - working capital
Long Term Debt [Line Items]
Long-term debt			3,715,088
Other Lenders | Note payable - equity investments
Long Term Debt [Line Items]
Long-term debt			3,270,427
Other Lenders | Note payable - management agreements
Long Term Debt [Line Items]
Long-term debt			640,466
Other Lenders | Note payable - assumption
Long Term Debt [Line Items]
Long-term debt			146,857
Other Lenders | Note payable - preferred interest redemption
Long Term Debt [Line Items]
Long-term debt			5,100,000
Other Lenders | Notes payable - settlements
Long Term Debt [Line Items]
Long-term debt			1,189,725
Other Lenders | Notes payable - THE
Long Term Debt [Line Items]
Long-term debt			311,149
Other Lenders | Notes payable - physician partners
Long Term Debt [Line Items]
Long-term debt			103,604
Other Lenders | Notes payable - acquisition
Long Term Debt [Line Items]
Long-term debt			$99,610
[1]	Effective rate as of December 31, 2014

Schedule_of_Applicable_Margins

Schedule of Applicable Margins Rate (Detail)	12 Months Ended
	Dec. 31, 2014
Debt Instrument [Line Items]
Senior debt ratio	176.00%
Maximum
Debt Instrument [Line Items]
Senior debt ratio	300.00%
Senior Debt Ratio, >=5x | Minimum
Debt Instrument [Line Items]
Senior debt ratio	250.00%
Senior Debt Ratio, 2.5x, but >=.0x | Minimum
Debt Instrument [Line Items]
Senior debt ratio	200.00%
Senior Debt Ratio, 2.5x, but >=.0x | Maximum
Debt Instrument [Line Items]
Senior debt ratio	250.00%
Senior Debt Ratio, 2.0 x | Maximum
Debt Instrument [Line Items]
Senior debt ratio	200.00%
Revolving Loan
Debt Instrument [Line Items]
Debt instrument applicable margin	3.75%
Revolving Loan | Senior Debt Ratio, >=5x
Debt Instrument [Line Items]
Debt instrument applicable margin	3.75%
Revolving Loan | Senior Debt Ratio, 2.5x, but >=.0x
Debt Instrument [Line Items]
Debt instrument applicable margin	3.25%
Revolving Loan | Senior Debt Ratio, 2.0 x
Debt Instrument [Line Items]
Debt instrument applicable margin	2.75%
Term Loan
Debt Instrument [Line Items]
Debt instrument applicable margin	4.25%
Term Loan | Senior Debt Ratio, >=5x
Debt Instrument [Line Items]
Debt instrument applicable margin	4.25%
Term Loan | Senior Debt Ratio, 2.5x, but >=.0x
Debt Instrument [Line Items]
Debt instrument applicable margin	3.75%
Term Loan | Senior Debt Ratio, 2.0 x
Debt Instrument [Line Items]
Debt instrument applicable margin	3.25%

Future_Maturities_LongTerm_Deb

Future Maturities Long-Term Debt (Detail) (USD $)	Dec. 31, 2014
Maturities Of Long Term Debt [Abstract]
2015	$5,023,048
2016	4,781,929
2017	4,613,541
2018	4,604,681
2019	4,625,161
Thereafter	$6,112,407

Preferred_Noncontrolling_Inter1

Preferred Noncontrolling Interests - Additional Information (Detail) (USD $)	12 Months Ended		4 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2013	Mar. 13, 2013	Oct. 31, 2013	Jul. 22, 2013	Dec. 31, 2014
Schedule Of Equity Method Investments [Line Items]
Common stock value	$1,638						$1,726
Amount of unreturned capital contribution and undistributed preferred distributions							10,000
Conversion price per share							$20
Outstanding preferred membership interest	8,700,000	11,072,465					8,700,000
Preferred member interest, annual cash dividends rate		11.50%
Business acquisition total consideration paid	2,339,905
Common Stock
Schedule Of Equity Method Investments [Line Items]
Total consideration	435,000		435,000
Number of shares sold	87,000		87,000
Foundation Health Enterprises LLC
Schedule Of Equity Method Investments [Line Items]
Offering cost			100,000	100,000	100,000
Number offering units					5
Common stock issued				1,000	1,000
Common stock value			5,000	5,000	5,000
Total consideration			8,700,000
Sale of units			87		87
Cumulative preferred annual return				9.00%
Foundation Health Enterprises LLC | Class B member interests
Schedule Of Equity Method Investments [Line Items]
Offering cost			105,000	105,000	105,000
Number offering units				152	87
Foundation Health Enterprises LLC | Private placement
Schedule Of Equity Method Investments [Line Items]
Offering cost			9,135,000	15,960,000	9,135,000
Tyche
Schedule Of Equity Method Investments [Line Items]
Cash paid as a part of consideration						11,102,372
Promissory notes issued as a part of consideration						2,339,905
Business acquisition total consideration paid						$13,442,277
Tyche | Five year warrants
Schedule Of Equity Method Investments [Line Items]
Warrants issued for purchase of common stock, units						193,750
Warrants issued for purchase of common stock, exercise price						$10
Tyche | Seven and one-half year warrants
Schedule Of Equity Method Investments [Line Items]
Warrants issued for purchase of common stock, units						351,620
Warrants issued for purchase of common stock, exercise price						$13.50
Tyche | Ten year warrants
Schedule Of Equity Method Investments [Line Items]
Warrants issued for purchase of common stock, units						229,630
Warrants issued for purchase of common stock, exercise price						$16

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]
Deferred rent	$3,930,325	$6,648,369
Rental expense net of sublease income for operating leases	9,933,563	7,112,362
Current and long-term deferred lease incentives	9,555,581	5,563,984
Self Insurance Reserves	$560,851

Summary_of_Future_Minimum_Leas

Summary of Future Minimum Lease Payments under Operating Leases (Detail) (USD $)	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
2015	$11,675,379
2016	11,760,275
2017	11,826,286
2018	11,737,775
2019	11,431,044
Thereafter	84,661,254
Less: Sublease income	-3,457,542
Total	$139,634,471

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jul. 22, 2013	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Provision for income taxes	$0	($851,788)	$3,777,113
Federal and state effective tax rate	38.00%	-42.00%	-36.00%
Operating loss carryforwards limitations on use		Due to the change of control resulting from the Foundation reverse acquisition, the Company will not be able to utilize the loss carryforwards.
Minimum
Income Taxes [Line Items]
Operating loss carryforwards, net		$30,000,000
Tax Year 2008
Income Taxes [Line Items]
Earliest tax year subject to examination		2008
Tax Year 2009
Income Taxes [Line Items]
Earliest tax year subject to examination		2009
Tax Year 2011
Income Taxes [Line Items]
Earliest tax year subject to examination		2011

Income_Tax_Provision_Detail

Income Tax Provision (Detail) (USD $)	0 Months Ended	5 Months Ended	12 Months Ended
	Jul. 22, 2013	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Current (provision) benefit			($302,464)	($4,078,826)
Deferred benefit			1,619,321	378,781
Increase in valuation allowance			-465,069	-77,068
Total (provision) benefit	0		851,788	-3,777,113
Tax benefit, discontinued operations		$514,371	$219,083	$514,371

Deferred_Income_Tax_Assets_and

Deferred Income Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred income tax assets:
Accounts receivable	$4,512	$135,983
Accounts payable	712,683	1,131,070
Accrued liabilities	260,655	338,901
Deferred rent and lease incentives	3,856,114	2,353,514
Stock compensation		202,453
Other assets	54,836	54,836
Total deferred tax assets	4,888,800	4,216,757
Valuation allowance	-779,358	-314,289
Net deferred tax assets	4,109,442	3,902,468
Deferred income tax liabilities:
Fixed assets	-1,267,740	-1,158,897
Intangible assets	-1,103,847	-1,725,099
Equity investments in affiliates	-861,869	-1,330,295
Prepaid and other current assets	-207,976	-174,419
Total deferred tax liabilities	-3,441,432	-4,388,710
Net deferred tax asset (liability)	$668,010	($486,242)

Balance_Sheet_Classification_o

Balance Sheet Classification of Deferred Income Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Current	$775,248	$2,118,637
Long-term	-107,238	-2,604,879
Net deferred tax asset (liability)	$668,010	($486,242)

Change_in_Valuation_Allowance_

Change in Valuation Allowance on Deferred Tax Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets Net Of Valuation Allowance [Abstract]
Beginning valuation allowance	$314,289
Reverse acquisition		237,221
Change in valuation allowance	465,069	77,068
Ending valuation allowance	$779,358	$314,289

Effective_Income_Tax_Rate_Deta

Effective Income Tax Rate (Detail)	0 Months Ended	12 Months Ended
	Jul. 22, 2013	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal statutory rate		34.00%	34.00%
State		4.00%	4.00%
Adjustment to prior year accrual		-23.00%
Permanent and other adjustments		-10.00%
Changes in valuation allowances		23.00%	-1.00%
Noncontrolling		-72.00%	16.00%
Impairment of goodwill			-79.00%
Impairment of investment			-6.00%
Other		2.00%	-4.00%
Effective income tax rate	38.00%	-42.00%	-36.00%

Capital_Structure_Additional_I

Capital Structure - Additional Information (Detail) (USD $)	12 Months Ended	4 Months Ended	0 Months Ended
	Dec. 31, 2013	Oct. 31, 2013	12-May-14	Jan. 08, 2015	Dec. 31, 2014
Equity Note [Line Items]
Common stock, shares outstanding	16,383,489				17,263,842
Common stock shares issued for liabilities owed to professional service providers	24,700
Common stock value for liabilities owed to professional service providers	$108,537
Common Stock
Equity Note [Line Items]
Total consideration	435,000	435,000
Number of shares sold	87,000	87,000
Common stock price per share	$5
Common stock shares issued for liabilities owed to professional service providers	24,700
Common stock value for liabilities owed to professional service providers	$2
Maximum
Equity Note [Line Items]
Common stock reverse split, conversion ratio			0.33
Minimum
Equity Note [Line Items]
Common stock reverse split, conversion ratio			0.1
Subsequent Event
Equity Note [Line Items]
Common stock reverse split, conversion ratio				0.1
Common stock, shares outstanding				17,263,842
Before Reverse Stock Split
Equity Note [Line Items]
Common stock, shares outstanding					172,638,414

Stock_Options_Grants_and_Warra2

Stock Options, Grants and Warrants - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 22, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized and reserved under incentive plan	2,000,000
Option issued		60,000
Fair value of option		$120,000
Compensation expense related to stock options	48,000	145,000
Warrant exercise price		$12.40	$14
Shares, Granted	971,755	23,000
Fair value of tyche warrants	936,000	936,000
Options and warrants outstanding, intrinsic value	0
Options and warrants exercisable, intrinsic value	0
Employee and Director
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, restricted stock units issued	971,755	230,000
Share based compensation arrangement by share based payment award fair value of restricted stock units released	3,518,000	113,000
Compensation expense recognized in period for restricted stock awards	1,337,000	130,000
Employee service share based compensation unrecognized compensation costs on restricted stock awards	$2,290,000	$165,000
Tyche | Five year warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants issued for purchase of common stock, units				193,750
Warrants issued for purchase of common stock, exercise price				$10
Tyche | Seven and one-half year warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants issued for purchase of common stock, units				351,620
Warrants issued for purchase of common stock, exercise price				$13.50
Tyche | Ten year warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants issued for purchase of common stock, units				229,630
Warrants issued for purchase of common stock, exercise price				$16
Warrant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, Granted		91,365
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant exercise price	$15

Assumptions_used_to_Value_Opti

Assumptions used to Value Option and Warrant Grants (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)	2 years 6 months
Volatility	58.00%
Risk free interest rate	0.35%
Dividend yield	0.00%	0.00%
Volatility, minimum		73.00%
Risk free interest rate, minimum		0.46%
Volatility, maximum		76.00%
Risk free interest rate, maximum		1.32%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)		2 years 6 months
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)		5 years

Information_with_Respect_to_St

Information with Respect to Stock Options and Warrants Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Options and Warrants
Number of options and warrants
Outstanding, ending balance	1,605,956	1,836,106
Weighted average exercise price, options and warrants
Weighted average exercise price, outstanding ending balance	$12.50	$12.91
Options and warrants outstanding, shares	1,605,956
Options and warrants exercisable, Shares	1,585,796
Stock Options and Warrants | Less than $5.00
Weighted average exercise price, options and warrants
Option and warrants, exercise price range, upper range limit	$5
Options and warrants outstanding, shares	102,000
Options and warrants outstanding, average remaining life (years)	4 years 7 months 6 days
Options and warrants outstanding, average exercise price	$4.59
Options and warrants exercisable, Shares	82,000
Options and warrants exercisable, average exercise price	$4.66
Stock Options and Warrants | $5.01 to $10.00
Weighted average exercise price, options and warrants
Option and warrants, exercise price range, lower range limit	$5.01
Option and warrants, exercise price range, upper range limit	$10
Options and warrants outstanding, shares	193,750
Options and warrants outstanding, average remaining life (years)	3 years 7 months 6 days
Options and warrants outstanding, average exercise price	$10
Options and warrants exercisable, Shares	193,750
Options and warrants exercisable, average exercise price	$10
Stock Options and Warrants | Greater than $10.00
Weighted average exercise price, options and warrants
Option and warrants, exercise price range, lower range limit	$10
Options and warrants outstanding, shares	1,310,206
Options and warrants outstanding, average remaining life (years)	3 years 10 months 24 days
Options and warrants outstanding, average exercise price	$13.48
Options and warrants exercisable, Shares	1,310,046
Options and warrants exercisable, average exercise price	$13.48
Warrant
Number of options and warrants
Reverse acquisition		857,242
Granted	1,500	866,364
Forfeited	-229,650
Weighted average exercise price, options and warrants
Weighted average exercise price, Reverse acquisition		$15.40
Weighted average exercise price, Granted	$5	$13.26
Weighted average exercise price, Forfeited	$15.82
Stock Option
Number of options and warrants
Reverse acquisition		56,250
Granted		60,000
Forfeited	-2,000	-3,750
Weighted average exercise price, options and warrants
Weighted average exercise price, Reverse acquisition		$13.30
Weighted average exercise price, Granted		$4.30
Weighted average exercise price, Forfeited	$12.50	$40

Information_with_respect_to_Re

Information with respect to Restricted Stock Awards (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Shares
Shares, Beginning balance	26,000
Shares, Reverse acquisition		4,375
Shares, Granted	971,755	23,000
Shares, Vested	-212,415	-1,375
Shares, Forfeited	-3,000
Shares, Ending balance	782,340	26,000
Weighted average grant date fair value
Weighted average grant date fair value, Beginning Balance	$4.70
Weighted average grant date fair value, Reverse acquisition		$11.11
Weighted average grant date fair value, Granted	$3.62	$4.90
Weighted average grant date fair value, Vested	$3.71	$28.80
Weighted average grant date fair value, Forfeited	$4.90
Weighted average grant date fair value, Ending Balance	$3.62	$4.70

Gains_and_Other_Item_Additiona

Gains and Other Item - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Aug. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Gain and Other Item [Line Items]
Total gain on El Paso Real Estate Transaction	$11,100,000	$11,069,839
Total consideration for Assignment Agreement with DOC		40,000,000
Estimated excess value of assets compared to consideration paid		4,027,562
Amount of certain liabilities forgiven		7,108,562	7,108,562
Annual rental payments		9,933,563	7,112,362
Legal and Closing Expenses
Gain and Other Item [Line Items]
Amount paid for certain legal and closing expenses		69,894
Capital lease obligations
Gain and Other Item [Line Items]
Amount of certain liabilities forgiven		714,824
Accrued and unpaid interest
Gain and Other Item [Line Items]
Amount of certain liabilities forgiven		467,132
Unpaid past due rent
Gain and Other Item [Line Items]
Amount of certain liabilities forgiven		2,767,905
Other accrued liabilities
Gain and Other Item [Line Items]
Amount of certain liabilities forgiven		3,158,701
Seller
Gain and Other Item [Line Items]
Purchase price of the property purchased under the agreement		39,066,428
DOC FSH El Paso Medical Center, LLC
Gain and Other Item [Line Items]
Amount retained by DOC as a security deposit		400,000
Hs Reit
Gain and Other Item [Line Items]
Amount paid to the company		463,678
OKC MOB Assignment Agreement
Gain and Other Item [Line Items]
Total consideration for Assignment Agreement with DOC		15,509,500
Amount paid to the company		4,885,328
Amount paid for certain legal and closing expenses		35,937
Area of building purchased under agreement		52,000
FMC
Gain and Other Item [Line Items]
Purchase price of the property purchased under the agreement		10,588,235
OKC DOC
Gain and Other Item [Line Items]
Sales lease back, terms		10 years
Annual rental payments		1,248,000
Percentage of annual lease escalations		2.00%
Income on underlying sub-lease		$900,000

Summary_of_Gain_on_Forgiveness

Summary of Gain on Forgiveness of Debt and Gain on Sale Leaseback of Real Estate (Detail) (USD $)	0 Months Ended	12 Months Ended
	Aug. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Other Income (Expense):
Gain on forgiveness of debt		$7,108,562
Gain on sale-leaseback of real estate		3,961,277	3,961,277
Total gain on El Paso Real Estate Transaction	$11,100,000	$11,069,839

Real_Estate_Transaction_Additi

Real Estate Transaction - Additional Information (Detail) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 01, 2014
Real Estate Properties [Line Items]
Annual rental payments	$9,933,563	$7,112,362
San Antonio Texas
Real Estate Properties [Line Items]
Operating Leases, Term of Contract			15 years
Annual rental payments			2,300,000
Percentage of annual lease escalations			3.00%
Income on underlying sub-lease			2,100,000
Cash received			$4,100,000

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jul. 22, 2013	Dec. 31, 2013	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Nonrecurring Basis [Line Items]
Goodwill impairment charge	$21,900,000	$21,864,781
Fair Value, Measurements, Nonrecurring
Fair Value Assets And Liabilities Measured On Nonrecurring Basis [Line Items]
Assets			$0

Fair_Value_Measurements_for_As

Fair Value Measurements for Assets Measured at Fair Value on Nonrecurring Basis (Detail) (Fair Value, Measurements, Nonrecurring, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Nonrecurring Basis [Line Items]
Assets		$0
Fair Value Measured on Nonrecurring Basis Gains (Losses), Total	-17,906,659
El Paso
Fair Value Assets And Liabilities Measured On Nonrecurring Basis [Line Items]
El Paso Real Estate Transaction	3,024,550
Fair Value Measured on Nonrecurring Basis Gains (Losses), Total	3,958,122
Foundation
Fair Value Assets And Liabilities Measured On Nonrecurring Basis [Line Items]
Assets	7,475,459
Liabilities	-15,401,366
Fair Value Measured on Nonrecurring Basis Gains (Losses), Total	-21,864,781
Significant Other Observable Inputs (Level 2) | El Paso
Fair Value Assets And Liabilities Measured On Nonrecurring Basis [Line Items]
El Paso Real Estate Transaction	2,573,633
Significant Unobservable Inputs (Level 3) | El Paso
Fair Value Assets And Liabilities Measured On Nonrecurring Basis [Line Items]
El Paso Real Estate Transaction	450,917
Significant Unobservable Inputs (Level 3) | Foundation
Fair Value Assets And Liabilities Measured On Nonrecurring Basis [Line Items]
Assets	7,475,459
Liabilities	($15,401,366)

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended	12 Months Ended	6 Months Ended	0 Months Ended
	Dec. 31, 2013	Mar. 13, 2013	Oct. 31, 2013	Jun. 01, 2014	Dec. 31, 2014	Dec. 31, 2013	Jul. 22, 2013	Dec. 30, 2014
Related Party Transaction [Line Items]
Related party deposit					$400,000
Common stock, shares issued	16,383,489				17,263,842	16,383,489
Common stock value	1,638				1,726	1,638
Total rental expense	211,787
Obligations owed to FHA and other affiliates	1,400,000					1,400,000		1,400,000
Foundation Health Enterprises LLC
Related Party Transaction [Line Items]
Common stock value		5,000	5,000
Offering cost		100,000	100,000
Number offering units			5
Common stock issued		1,000	1,000
Foundation Health Enterprises LLC | Class B member interests
Related Party Transaction [Line Items]
Offering cost		105,000	105,000
Number offering units		152	87
Foundation Health Enterprises LLC | Chief Executive Officer
Related Party Transaction [Line Items]
Offering cost			525,000
Foundation Health Enterprises LLC | Private placement
Related Party Transaction [Line Items]
Offering cost		15,960,000	9,135,000
Minimum
Related Party Transaction [Line Items]
Management fee Percentages range					2.25%
Maximum
Related Party Transaction [Line Items]
Management fee Percentages range					6.00%
New Sleep Lab International, Ltd.
Related Party Transaction [Line Items]
Income on underlying sub-lease				8,767
Sublease expiration date				30-Nov-18
Lease expense					60,300
Valliance Bank
Related Party Transaction [Line Items]
Notes payable	5,900,000					5,900,000
Shareholders And Affiliates | Minimum
Related Party Transaction [Line Items]
Interest rates on the notes					5.00%
Shareholders And Affiliates | Maximum
Related Party Transaction [Line Items]
Interest rates on the notes					10.00%
City Place
Related Party Transaction [Line Items]
Lease expense					145,945	57,000
Lease agreement monthly rent description					The Company pays monthly rent of $17,970 until June 30, 2014; $0.00 from July 1, 2014 to January 31, 2015 and $17,970 from February 1, 2015 to March 31, 2017 plus additional payments for allocable basic expenses of City Place
Lease expiration date					31-Mar-17
Roy T. Oliver
Related Party Transaction [Line Items]
Percentage of ownership in shareholders and affiliates							5.00%
Common stock, shares issued							1,797,030
Common stock value							$8,136,390

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail)	Dec. 31, 2014	Dec. 31, 2013	Jan. 01, 2015
Foundation Surgery Affiliate of Northwest Oklahoma City LLC | Oklahoma City OK
Subsequent Event [Line Items]
Equity investments, ownership interest	20.00%	20.00%
Subsequent Event | Summit Medical Center L L C
Subsequent Event [Line Items]
Cost method investment ownership percentage			8.00%
Subsequent Event | Foundation Surgery Affiliate of Northwest Oklahoma City LLC | Oklahoma City OK
Subsequent Event [Line Items]
Equity investments, ownership interest			20.00%
Subsequent Event | Foundation Surgery Affiliate of Northwest Oklahoma City LLC | Oklahoma City OK | Summit Medical Center L L C
Subsequent Event [Line Items]
Percentage of ownership exchanged through assets other than cash and accounts receivable			40.00%